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In 2013, the Department of Health’s Tobacco Policy Review Group published the report Tobacco Free Ireland, 
which set a target for Ireland to reduce smoking prevalence to less than 5% by 2025. Tobacco Free Ireland was 
the first policy document to be launched under the Department of Health’s Healthy Ireland framework, and it 
was endorsed by the Government. Achieving the 5% smoking prevalence target in the reduction of smoking 
prevalence would play a major role in realising the vision set out in Healthy Ireland. The Tobacco Free Ireland 
report identified tobacco-related harm reduction as a key issue for consideration. It specifically highlighted the 
role of electronic cigarettes (e-cigarettes) as a potential harm reduction strategy. Since the introduction of e-
cigarettes in 2006, research has expanded on the potential benefits and public health harms of e-cigarettes. 
This systematic evidence review outlines what is known to date about e-cigarette and heat-not-burn tobacco 
devices’ efficacy in terms of smoking cessation in randomised controlled trials (RCTs) and adverse events 
recorded in those trials, which will help to inform the Department of Health’s policy position with respect to e-
cigarettes.  
Questions 
• What is the efficacy and safety of e-cigarettes in helping people who smoke to achieve abstinence 
(smoking cessation)? 
• What is the efficacy and safety of heat-not-burn tobacco products in helping people who smoke to achieve 
abstinence (smoking cessation)? 
Methods 
We used systematic review techniques to complete this review. These included a systematic search, double 
screening, assessment of bias, formal extraction of data and a feasibility assessment to decide if we should do 
meta-analysis. Searches were carried out in February 2020 in the following databases: Ovid MEDLINE, 
Cochrane Library, and Elsevier Embase. We searched for randomised controlled trials (RCTs) of e-cigarettes or 
heat-not-burn tobacco products compared with electronic non-nicotine delivery systems (ENNDS) or placebo 
heat-not-burn tobacco products, or any comparator treatment or combination of treatments usually given for 
smoking cessation. Our primary outcome of interest was smoking cessation as defined by European Medicines 
Agency guidance, measured at 6 months or 1 year after treatment initiation. Verified data were preferred, but 
self-reported data were also included. In addition, we extracted data on adverse events.  
We analysed the trial data using network meta-analysis, which is a statistical technique for comparison of 
three or more treatments in a single analysis by combining direct and indirect evidence in a single network. 
We used the ‘gemtc’ package in R version 3.6.0 to conduct a network meta-analysis of smoking cessation at 6 
months for e-cigarette trials.  
Findings: e-cigarettes 
Study characteristics 
Nine RCTs reported in 15 publications met the inclusion criteria for efficacy (N=7) and safety (N=9) of e-
cigarettes in helping people who smoke to achieve abstinence (smoking cessation). Two trials reported safety 
data only. The number of participants in the RCTs ranged from 30 to 2,012. Of the nine trials, two were based 
in Italy, three in the USA, two in the UK, and one each in South Korea and New Zealand. On average, 
participants in the included RCTs were males aged 40–50 years who were dependent, heavy smokers. The 
participants were a mix of those who were motivated to quit and those who had no intention to quit. One trial 
appeared to include lighter smokers, and the influence of this trial on the network meta-analysis was 
examined through a sensitivity analysis.  
The two studies included for safety data only allowed participants to have nicotine doses of 24-48mg/mL.  
Smoking cessation data reported at 24 or 26 weeks and 52 weeks were included. Self-reported data, which 
was then biochemically verified, was preferred over self-reported status only, and unverified data was 
excluded in a sensitivity analysis to test its impact on the overall network meta-analysis results. 
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Risk of bias 
The HRB carried out a risk of bias analysis using the Cochrane Risk of Bias (Version 2) tool for randomised trials. 
Of the included nine RCTs, eight were at a high risk of bias. These ratings were mainly driven by missing 
outcome data. The numbers lost to follow-up were high in nine RCTs, and the proportions of successful 
cessation events were low in the RCTs, both of which introduced uncertainty to the results of this systematic 
review. 
Smoking cessation 
The network meta-analysis of smoking cessation at 24 or 26 weeks is based on seven RCTs.  
Using NRT as the reference treatment, the incidences of smoking cessation at 24 or 26 weeks are very similar 
in both the ENDS and the NRT groups (RR: 1.17; 95% Credible Interval [CrI]: 0.61–1.99), which indicates there is 
no evidence for a difference in effect. Electronic non-nicotine delivery systems (ENNDS) are somewhat less 
effective in achieving smoking cessation than NRT (RR: 0.65; 95% CrI: 0.24–1.42), but the result is not 
statistically significant. NRT is more effective than no additional treatment and this result is statistically 
significant (RR:0.35; 95% CrI: 0.11-0.88). 
Three sensitivity analyses were carried out. The first excluded the RCT which appeared to include lighter 
smokers, the second included only those RCTs which had biochemically verified their smoking data, and the 
third excluded the study with a lower dose of nicotine from the ENDS arm. The results of these sensitivity 
analyses indicate that the main analysis is robust to assumptions relating to the smoking history of participants 
and inclusion of unverified data, and marginally less robust to the assumption of nicotine dose. 
The HRB was unable to undertake a network meta-analysis of smoking cessation at 52 weeks due to limited 
data; only three RCTs reported data for this timepoint.  
Findings: heat-not-burn tobacco products 
There were no RCTs that met the inclusion criteria for the question on efficacy of heat-not-burn tobacco 
products in helping people who smoke to achieve abstinence (smoking cessation). 
Two studies reported adverse event data for heat-not-burn tobacco products. The Cochrane Risk of Bias 
(Version 2) tool was used to assess risk of bias in these two RCTs and both were found to be at a high risk of 
bias. No conclusions could be reached from these data and further research is needed if these tobacco 
products are to be considered as a safe smoking cessation tool. 
Adverse events:  e-cigarettes and heat-not-burn tobacco products 
This systematic review found that standardised definitions were not used to collect data on adverse events in 
all of nine included studies. Data on several of the adverse event categories recommended for observation by 
the European Medicines Agency were not captured in all the included studies. These included the 
cardiovascular category (where only three out of the nine studies reported adverse event findings) and the 
psychiatric category (where, once again, only three out of the nine studies reported findings). 
Pulmonary events were consistently monitored in six of the nine trials studied. Respiratory symptoms that 
were collected included shortness of breath and cough. For all reported adverse events, the incidence was 
lower in the control arms (NRT or ENNDS) than in the e-cigarette arm, except for shortness of breath in one 
study and cough in one study. 
No serious adverse events were designated as being related to treatment in the four studies that reported 
serious adverse events; however, the procedure for determining if a serious adverse event was related to the 
smoking cessation intervention was often unclear. 
The adverse events in this study were all collected over a short period of time (≤ 12 months), and longer-term 
studies are therefore needed in order to fill this knowledge gap. 
Level and certainty of evidence 
We assigned a Level 2 evidence rating using the Centre for Evidence-Based Medicine levels of evidence 
guidelines, as we had seven RCTs in the network meta-analysis, but six of the seven trials had a high risk of 
bias. With respect to the certainty of evidence, we believe that there is low certainty of evidence that e-
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cigarettes have the same levels of success in achieving smoking cessation as other medically approved (by the 
Health Products Regulatory Authority in Ireland or the European Medicines Agency) cessation interventions, 
based on the results of the network meta-analysis at 6 months, because of the high risk of bias in six of the 
seven trials, the low number of successful events in the trials, and the high dropout rates. 
There is a very low certainty of evidence that e-cigarettes have the same levels of success in achieving smoking 
cessation as other medically approved cessation interventions, based on three trials, for smoking cessation at 
52 weeks, and therefore results are inconclusive.  
For heat-not-burn tobacco products, there is a very low (or no) certainty of evidence for using these tobacco 
products as a smoking cessation intervention.  
Strengths and limitations 
The main strength of this systematic review is that it used a comprehensive search strategy that is likely to 
have captured all relevant trials and that it adds five new trials to the statistical synthesis by Cochrane, leading 
to an updated systematic review of the topic.  
The main limitation of this review is that e-cigarettes are not a standardised intervention. A variety of first- and 
second-generation e-cigarettes were tested, and the nicotine doses varied.  
Other limitations of this review are the small sample sizes in the examined trials and the low number of 
participants achieving smoking cessation. Seven RCTs reported smoking cessation at 24 or 26 weeks, and only 
three of those also reported smoking cessation at 52 weeks. In addition, loss to follow-up was very high and 
exceeded 20% in at least one arm of eight of the nine included trials  
During the 12-week observation period that followed the active treatment period, participants could purchase 
further smoking cessation therapies; these data were not recorded by most of the trials. One trial asked 
participants to sign a commitment not to use the non-assigned treatment for at least 4 weeks after their quit 
date. 
The power of the comparisons between the comparator arms of the HRB’s network meta-analysis would have 
been increased if we had widened our inclusion criteria to RCTs examining medically approved cessation 
therapies as well as behavioural therapies that were not compared directly to e-cigarettes. However, our brief 
was to examine the efficacy of e-cigarettes and their contribution to smoking cessation.   
Conclusions 
The systematic review and network meta-analysis of electronic nicotine delivery systems (e-cigarettes) versus 
therapies usually given for smoking cessation showed that there is no evidence of a difference in effect on 
incidences of smoking cessation. There is a low-level of certainty in these results due to low successful event 
rates and high rates lost to follow-up in all studies.  
The systematic review of evidence for heat-not-burn tobacco products showed that there is no evidence from 
RCTs on efficacy for smoking cessation compared with current standard care, and insufficient evidence on the 
safety of heat-not-burn tobacco products from RCTs. 
Identified respiratory adverse events, including shortness of breath and cough, appeared to be higher in 
electronic nicotine delivery systems users, but in the main, RCT evidence on adverse events is lacking. The 
long-term data on electronic nicotine delivery systems, in line with European Medicines Agency 
recommendations, are limited for both smoking cessation and adverse events, and further large-scale research 




1.1 Policy background 
In 2013, the Tobacco Policy Review Group published Tobacco Free Ireland, a report which set a target for 
Ireland to reduce smoking prevalence to less than 5% by 2025.1 Tobacco Free Ireland was the first policy 
document to be launched under the Healthy Ireland framework, and it was endorsed by the Government. 
Achieving the target in the reduction of smoking prevalence would play a major role in realising the vision set 
out in Healthy Ireland.  
The Tobacco Free Ireland report identified tobacco-related harm reduction as a key issue for consideration.1 It 
specifically highlighted the role of electronic cigarettes (e-cigarettes) as a potential harm reduction strategy. 
Since e-cigarettes’ launch in the European Union (EU) in 2006 and in the United States of America (USA) in 
2007, research on their potential benefits in terms of tobacco-related harm reduction, and on the public 
health harms of e-cigarettes, has grown.  
The DOH asked the Health Research Board (HRB) to complete a programme of research and to answer five 
research questions: 
1. What are the public health benefits and harms of e-cigarettes? 
2. What are the public health benefits and harms of heat-not-burn tobacco products? 
3. What is the efficacy and safety of e-cigarettes in helping people who smoke to achieve abstinence 
(smoking cessation)? 
4. What is the efficacy and safety of heat-not-burn tobacco products in helping people who smoke to achieve 
abstinence (smoking cessation)? 
5. Does e-cigarette use by adolescents who are cigarette naive at baseline lead to subsequent cigarette 
smoking? 
1.2 Research questions 
We answer the following questions in this systematic review: 
• What is the efficacy and safety of e-cigarettes in helping people who smoke to achieve abstinence 
(smoking cessation)? 
• What is the efficacy and safety of heat-not-burn tobacco products in helping people who smoke to achieve 




2.1 E-cigarette devices 
It is generally accepted that e-cigarettes were launched in the EU in 2006 and in the USA in 2007. Since then, 
the e-cigarette industry has represented a burgeoning dynamic market with rapid product innovation. E-
cigarettes encompass a wide range of battery-operated devices that vaporise or, more correctly, aerosolise 
nicotine and other contents for inhalation. There are currently four generations of e-cigarettes. As of 2014, 
more than 460 different e-cigarette brands and 7,000 unique electronic liquid (e-liquid) flavours were reported 
to have been for sale on English-language Internet sites.2 These numbers are likely to have increased 
considerably between 2014 and 2019.  
2.2 Existing research on e-cigarettes and smoking cessation 
We identified two systematic reviews and a health technology assessment that investigated the effect of e-
cigarette use on smoking cessation. 
2.2.1 Systematic reviews 
Using a systematic review approach, Hartmann-Boyce et al. evaluated the safety and effect of using e-
cigarettes to help people who smoke to achieve ‘long-term smoking abstinence’.3 They included people 
defined as current smokers at the time of their enrolment into the studies, where participants could be 
motivated or unmotivated to quit.3 The authors included randomised controlled trials (RCTs) in which smokers 
were randomised to e-cigarettes or to a control intervention, which measured abstinence rates at 6 months or 
longer in order to determine the efficacy of e-cigarettes as an aid to smoking cessation. For adverse events and 
biomarkers, the authors included randomised crossover trials and cohort follow-up studies with a follow-up of 
greater than 1 week. They compared nicotine e-cigarettes to non-nicotine or placebo e-cigarettes; e-cigarettes 
to alternative smoking cessation aids, including nicotine replacement therapy (NRT) or no intervention; and e-
cigarettes used in combination with standard smoking cessation treatment (behavioural or pharmacological or 
both) to standard treatment alone. They measured cessation at the longest follow-up point, which was at least 
6 months from the start of the intervention, and “using the strictest definition of abstinence”.3(p8) The authors 
only identified two completed RCTs4,5 that contributed data on cessation at 6 months or longer.  
Hartmann-Boyce et al. concluded that a limited number of RCTs had been reported; hence, certainty about the 
effects of e-cigarettes on smoking cessation was low. They noted that more data are needed in order to 
“strengthen confidence in the estimates”,3(p23) and there was evidence from the pooled results of two trials 
that e-cigarettes with nicotine, compared with placebo e-cigarettes, helped smokers to stop smoking long 
term. They added that there was evidence from one trial that e-cigarettes may lead to 6-month quit rates 
similar to those achieved with NRT, but that the confidence interval (CI) was wide. They also acknowledged 
that “e-cigarettes are an evolving technology and the effects of newer devices with better nicotine delivery are 
unknown”.3(p. 23)  
El Dib et al. also conducted a systematic review focusing on e-cigarettes and smoking cessation, and they 
reported similar findings to Hartmann-Boyce et al.6 Using pooled data from two RCTs with a combined total of 
481 participants, they concluded that there was evidence for a possible increase in tobacco smoking cessation 
success rates when e-cigarettes were used in comparison with electronic non-nicotine delivery systems – that 
is, a placebo e-cigarette without nicotine.6 However, the authors point out that the 95% CI of the relative risk 
crossed 1.0, and therefore the evidence was of low certainty. 
2.2.2 Health technology assessment 
The Health Information and Quality Authority (HIQA) carried out a health technology assessment of smoking 
cessation interventions in Ireland. The assessment aimed to examine the clinical effectiveness, safety, and 
cost-effectiveness of smoking cessation interventions, in addition to the organisational, societal, and ethical 
implications of “potential changes to the mix of treatments that people use to help them stop smoking”.7(p10) 
Two trials were pooled, and neither of the trials reported a statistically significant benefit. Both trials had 
absolute quit rates in the control and intervention arms that were low compared with average absolute quit 
rates in trials of NRT. The report concluded that due to the limited number of RCTs and the rapidly evolving 
range of e-cigarette products, there is a high level of uncertainty regarding the clinical effectiveness and cost-
effectiveness of e-cigarettes. It also noted that the long-term health effects of e-cigarettes are unclear, and 
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highlighted concerns that “their widespread promotion by health professionals could normalise nicotine 





This systematic review is part of a wider project assessing the public health harms and benefits of e-cigarettes 
and heat-not-burn tobacco products; a single standard systematic search approach was used for the five 
questions outlined in Section 1.1. The methods in this section refer to question 3 and 4 only.  
3.1 Information searches 
Literature searches were carried on the 26 and 27 February 2020. The databases used were Ovid MEDLINE, 
Elsevier Embase (www.embase.com) and the John Wiley & Sons Cochrane Library, including Cochrane 
CENTRAL. The full search strategies for these searches are available from Appendix A. The concepts included in 
the search were e-cigarettes/heat-not-burn tobacco products, and randomised controlled trials (RCTs). For the 
MEDLINE search, the Cochrane highly-sensitive RCT filter was used.8 Search results (n=1,880; of which Ovid 
MEDLINE n=344, Embase n= 827, Cochrane (trials only) n=709) were combined and deduplicated in Endnote 
X9.1. When duplicates were removed the number was reduced to 1,396. These results were dual screened by 
the researcher (JQ) and the information specialist (CL). 
3.2 Eligibility criteria 
The eligibility criteria used in this systematic review is given in Table 1. 
The European Medicines Agency recommends continuous smoking abstinence (smoking cessation) as the 
primary endpoint in trials of medicinal products.9 The European Medicines Agency concedes that while 
different terms may be used for the smoking cessation outcome in trials, its definition should reflect 
continuous abstinence rate without slips or episodes of relapse to smoking throughout the follow-up period 
and this is the definition which the HRB used in this systematic review. This guidance also recommends a 12-
month endpoint for analysis. However, many trials only report up to the 6-month timepoint, and so we have 
included both 6-month (24 or 26-week) and 12-month (52-week) timepoints. 
Table 1 Eligibility criteria 
Element Inclusion Exclusion 
Population Current regular smokers Non-smokers 
Subgroups of smokers; pregnant women and 
those with mental health illness 
Dual users 
Intervention E-cigarette (electronic device containing nicotine) 
± usual care (i.e. smoking cessation counselling), or 
heat-not-burn tobacco products ± usual care (i.e. 
smoking cessation counselling) 
Time on treatment ≥6 weeks 
E-cigarettes in combination with other active 
treatments such as NRT or pharmacological 
interventions 
Control  Placebo e-cigarette (without nicotine) or any 
comparator treatment or combination of 
treatments usually given for smoking cessation 
Regular cigarettes 
Denicotinized cigarettes 
Outcomes Smoking cessation: Continuous abstinence 




Study design RCTs Crossover design 
Conference abstracts 
Language Studies published in English  
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In order to undertake a statistical analysis as described in section 3.6, one treatment must be specified as a 
reference treatment against which all other treatments will be compared. For this analysis, we have selected 
NRT as the reference treatment because it is currently recommended for use in Ireland,7,10 and because it was 
a common control treatment in the RCTs identified. 
3.3 Screening 
Studies were compared against the inclusion criteria in Section 3.2 in order to determine inclusion. Abstracts 
(JQ and CL) and full-text articles (JQ, JL and CL. JL and CL split one round of screening) were screened 
independently by two researchers, and disagreements were resolved by discussion until a consensus was 
reached. 
3.4 Data extraction 
Data were extracted into a bespoke data extraction form by a single reviewer (HK), and data were verified by a 
second reviewer (JQ). The following data were extracted: 
• Date and place of publication 
• Study design  
• RCT inclusion and exclusion criteria 
• Study participant characteristics 
• Summary of intervention and control conditions 
• Number of participants in each arm 
• Smoking cessation outcomes 
• Biochemical validation  
• Adverse events, and 
• Assessment timepoints. 
3.4.1 Adverse events 
Adverse events are undesirable symptoms which occur during a trial and may or may not be related to the 
treatment given. As well as referring readers to specific guidance for safety assessments in clinical trials, the 
European Medicines Agency lists specific adverse events of interest:9 
1. Interactions 
2. Vital signs 
3. Psychiatric adverse events 
4. Cardiovascular and pulmonary compromised patients 
5. Nicotine-conjugate antigens, and 
6. Rebound and withdrawal and addiction potential. 
As this study focused on RCTs only, we did not extract data on interactions; interactions tend to be the focus of 
non-RCTs conducted earlier in the medicinal product development cycle. We also did not extract data on 
nicotine-conjugate antigens, as vaccinations against nicotine were not interventions or comparators of 
interest. Therefore, we extracted data for the remaining four adverse events categories (splitting 
cardiovascular and pulmonary adverse events into two categories). In addition, we included a category for 
serious adverse events, as serious adverse events should be routinely reported by clinical trials. The European 
Medicines Agency guidelines also suggest that measures should, at a minimum, be taken at baseline, during 
active treatment, immediately after the end of treatment, and at 6- or 12-month follow-up.9 
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3.5 Quality assessment 
JQ, HK and JL assessed the risk of bias for the included RCTs using Version 2 of the Cochrane risk-of-bias tool 
for randomised trials – ‘RoB 2’.11 This tool uses five groups of items to assess the level of bias in the design, 
conduct, and analysis of RCTs. The five groups of items are: randomisation process, deviations from intended 
intervention(s), missing outcome data, measurement of the outcome, and selection of the reported results. 
Each RCT was independently assessed by the researchers, with any disagreements resolved by consensus. We 
did not use our assessment of bias results to exclude studies from the main analysis, but the assessment was 
used to describe the main strengths and limitations of the studies. 
3.6 Data analysis: network meta-analysis 
Network meta-analysis (NMA) is a statistical technique for comparison of three or more treatments in a single 
analysis by combining direct and indirect evidence in a single network.12 We applied this technique to evidence 
collected by the systematic review methods. Before the analysis was undertaken, a feasibility assessment was 
conducted to assess the feasibility and appropriateness of undertaking an NMA, and this is described in 
Section 6.7.  
3.6.1 Evidence networks 
Evidence networks were drawn for endpoints that were reported in three or more trials, and the geometry of 
the networks was analysed. This geometric analysis determined whether NMA would be feasible. 
Indirect treatment comparisons, based on the Bucher method, were considered for endpoints which could not 
be analysed through NMA.13 Indirect treatment comparisons were only conducted if the analysis could 
strengthen the comparison of electronic nicotine delivery systems (ENDS) with the reference treatment, NRT.   
Network plots are presented against the results of those analyses that were deemed feasible in Section 7 of 
this report. The lines in the network plot are proportional to the strength of the evidence, i.e. the number of 
studies informing that comparison. 
3.6.2 Model for analysis 
Analysis was conducted in a Bayesian framework in R version 3.6.014 using the ‘gemtc’ package.15 Neupane et 
al. reviewed the packages that were available for conducting NMA in R,16 and based on the results presented 
in the review and the advice of peer-reviewers, the ‘gemtc’ package was deemed to be most suitable, as it 
allows for arm-based data to be analysed and the package can summarise the comparative treatments effects 
as relative risks. Using an arm-based approach can help to avoid some of the difficulties which arise from 
including multi-arm trials in an NMA.17  
The HRB specified the following parameters: 250,000 ‘burn-in’ iterations to be discarded, 500,000 iterations 
for the analysis, and three separate chains. Diagnostic tests were run to check model convergence. Thinning of 
the chains was specified to reduce the risk of autocorrelation. Default priors as specified by the ‘gemtc’ 
package were used. 
3.6.3 Endpoints and methods to handle missing data 
As outlined in Section 3.2, we followed the European Medicines Agency definition of abstinence. The European 
Medicines Agency also recommended that self-reported smoking status should be verified by biomarkers such 
as carbon monoxide; therefore, we extracted verified self-reported data as the preference, but we used self-
reported data when verified data was not available.  
For the 6-month timepoint data, we considered data published at both 24 weeks and 26 weeks, as both of 
these timepoints were used by the identified RCTs.  
Relative risks for the efficacy endpoints were computed for individual studies for comparison purposes if these 
were not reported for the RCT in the original paper. These were not used in the NMA. However, binary counts 
were entered instead, as this was the requirement of the analytical programme.  
3.6.4 Heterogeneity 
Heterogeneity between studies was examined qualitatively by examining the study eligibility criteria and 
baseline characteristics of participants in the trials. Sensitivity analyses were conducted to assess the impact of 
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identified heterogeneity. Heterogeneity was quantitatively estimated using tau and is presented alongside the 
full results of each analysis in Appendix E. 
Meta-regression was considered as an approach to assess the impact of heterogeneity, for example including 
nicotine dose as a covariate, however, there were an insufficient number of studies identified to reliably carry 
out a meta-regression. 
The results of random effects models only are presented because of identified points of heterogeneity 
between studies; random effects models allow for more conservative estimates of effect where there is 
heterogeneity.18 
3.6.5 Inconsistency assessment 
A key assumption of NMA is that of evidence consistency. The requirement is that in every trial in the network, 
regardless of the actual treatments that were compared, the true effect of treatment Y relative to treatment X 
is exchangeable between trials.19 This exchangeability assumption can be tested in an inconsistency 
assessment. The HRB intended to carry out an inconsistency assessment using the Bucher method, as this is 
the simplest method and therefore preferred for transparency reasons.13,17-19 All loops in the network were 
identified and considered for this assessment. However, on close examination of the data, we were unable to 
use this method due to the presence of muti-arms trials which affected the independence of the loops. Where 
independent tests cannot be constructed, Dias et al. suggested that the standard consistency model be 
compared with an inconsistency model.19 To check whether the consistency assumption as assumed in the 
NMA is reasonable for a dataset, Dias et al. suggested that we can compare that NMA model with a model 
where no such consistency is assumed. By looking at model fit statistics (deviance information criterion) we 
can assess whether eliminating the assumption of consistency for all contrasts has resulted in a better fitting 
model. We have compared the main model (consistency model) against an inconsistency model that assumes 
unrelated mean (relative) effects using a function of the ‘gemtc’ package.15 
We also compared the direct head to head meta-analysis results versus the NMA outputs to check for 
potential inconsistency. Meta-analyses for the direct comparisons were run using the ‘Metagen’ package for 
the R programming language.20,21 This package uses the inverse variance method for weighting of studies.20,21 
3.6.6 Presentation of results 
In order to undertake an NMA, one treatment in the network must be specified as a reference treatment 
against which all other treatments will be compared. For this analysis, we have selected NRT as the reference 
treatment because it is currently recommended for use in Ireland,7,10 and because it was a common control 
treatment in the RCTs identified. 
Results of the analysis are presented as median relative risks (RRs) with associated 95% credible intervals (95% 




4 Search results 
From an initial 1,396 studies, 11 RCTs reported in 19 publications met the inclusion criteria for this systematic 
review. 
An overview of the number of studies included and excluded at each stage of screening is given in Figure 1. A 
list of the included studies, giving their primary and secondary publications, is presented in Table 2. We have 
assigned each of the studies an identification code (ID), which is based on the trial name or the first author’s 
name and date if no trial name was reported, and we will use this ID throughout the report. Studies excluded 
at full-text screening are tabulated alongside the reason for exclusion, and are presented in Appendix B. 
There were no RCTs that met the inclusion criteria for the question on efficacy of heat-not-burn tobacco 
products in helping people who smoke to achieve abstinence (smoking cessation) but two studies reported on 
adverse events.22,23 
Of the 11 trials, four were two-arm trials,24-27 five were three-arm trials,4,5,22,23,28, one was a four-arm trial,29 
and one was a five-arm trial.30 
Haziza 2019, Ludicke 2018 and Hatsukami 2019 all contained conventional cigarette arms which were excluded 
and the fourth arm of the Hatsukami trial which assigned users to dual use was excluded.22,23,29 The five-arm 
Halpern et al. 2018 trial comprised three arms that did not meet the systematic review inclusion criteria, and 
therefore only two of that trial’s study arms are included in this report.  
The number of participants in the RCTs ranged from 3026 to 2,012.30 Of the 11 trials, two were based in 
Italy,5,28, four in the USA26,29-31, two in the UK24,27 and one each was based in South Korea,25 Japan,23 and New 
Zealand.4 Table 2 also gives the comparators from each of the trials. Heat-not-burn tobacco products or ENDS 
was the intervention in all trials, and it was compared against NRT single or combination treatments, placebo 
e-cigarettes (Electronic non-nicotine delivery systems, ENNDS), and no additional treatment. The comparisons 
from the trials indicated that network meta-analysis was possible; however, before any analysis was 
undertaken, it was necessary to conduct a feasibility assessment.  
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Full-text articles assessed 
for eligibility 
(n=32) 
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(n=13) 
Studies included in quantitative 
synthesis  
(n = 19) 
 
2 RCTs reported in 4 publications for 
heat-not-burn products 
 
9 RCTs reported in 15 publications for 
ENDS 
Figure 1 PRISMA flow chart 
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5 Results of systematic review for heat-not-burn tobacco products 
As outlined in section 4, two studies reporting data for heat-not-burn tobacco products were identified.22,32 
The Ludicke 2018 trial was carried out in Japan and the Haziza 2019 trial was carried out in the USA. Both 
studies reported safety data only. 
In Ludicke 2018, participants were randomised to one of three arms; the menthol Tobacco Heating System 2.2, 
continuing smoking and smoking abstinence only.32 Only the Tobacco Heating System 2.2 and the smoking 
abstinence arms are relevant to this systematic review. Participants were monitored for five days in 
confinement and 85 days in an ambulatory setting giving a three-month trial period. In this RCT, 78 
participants were randomised to the Tobacco Health System 2.2 and 40 to smoking abstinence. The mean age 
of participants was 37.2 years and 57.5% of participants were male. 
Haziza 2019 followed the same trial design as Ludicke 2018 but was conducted in the USA. In this study 80 
participants were randomised to the Tobacco Heating System 2.2 arm and 39 were assigned to smoking 
abstinence. The mean age of participants was 37.7 years and 60% of participants were male.  
5.1 Risk of bias 
We assessed studies for a risk of bias using the Cochrane RoB 2 tool.11 The overall risk of bias in the two heat-
not-burn tobacco product RCTs was high as shown in Figure 2. A full explanation of the assignment of the risk 
of bias criteria is given in Appendix C. A breakdown of missing data in the RCTs is given in   
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Table 3; there was a very high number of participants with missing data in Haziza 2019. 
 
Figure 2 Risk of bias in the heat-not-burn tobacco product RCTs 
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Table 3 Missing data in heat-not-burn tobacco product RCTs 
 
Total allocated 








Haziza 2019       
Tobacco Heating 
system 
80 4 2 25 2 33 
Smoking abstinence 39 5 3 21 6 34 
       
Ludicke 2018 
      
Tobacco Heating 
system 
78 - - - 2 2 
Smoking abstinence 40 - - - 2 2 
 
5.2 Adverse events 
The adverse events of interest in the Haziza 2019 trial which were reported by more than one participant 
following randomisation are reported in Table 4. 
Table 4 adverse events of interest in Haziza 2019 
Adverse event Tobacco Heating System Smoking abstinence 
Participants with any adverse events 52 (65.0) 23 (59.0) 
Infections and infestations 5 (6.3) 1 (2.6) 
      Upper respiratory tract infection 3 (3.8) 1 (2.6) 
Respiratory, thoracic, and mediastinal disorders 9 (11.3) 3 (7.7) 
     Cough 3 (3.8) 0 
     Nasal congestion 3 (3.8) 0 
     Oropharyngeal pain 2 (2.5) 1 (2.6) 
     Sinus congestion 1 (1.3) 1 (2.6) 
 
The adverse events of interest that were observed in at least 5% of participants in the Ludicke RCT are 




Table 5 Adverse events of interest in Ludicke 2018 
 Adverse event Tobacco Heating System Smoking abstinence 
Participants with any adverse events 32 (41.0%) 14 (35.0%) 
Infections and Infestations 6 (7.7%) 3 (7.5%) 
  Nasopharyngitis 3 (3.8%) 2 (5.0%) 
  Hordeolum 1 (1.3%) 0 
  Pharyngitis 1 (1.3%) 0 
Psychiatric disorders 0 1 (2.5%) 
  Insomnia 0 1 (2.5%) 
 
A summary of the adverse events that were reported in the studies overall is given in Table 6. The Minnesota 
Nicotine Withdrawal Scale was used in both studies. 
Table 6 Studies documenting adverse events as recommended by the European Medicines Agency  
Study ID Vital signs Psychiatric Cardiovascula
r 









Y Y N Y* Y N 
Haziza 
2019 
Y Y N Y Y Y 
*Pulmonary related infections 
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6 Results of the systematic review for e-cigarettes 
6.1 Eligibility criteria of RCTs 
Data on eligibility criteria related to smoking history were extracted from the included RCTs and are given in 
Table 7. Five trials required participants to be smoking at least 10 cigarettes per day.4,5,25,27,28 The criteria for 
the length of time participants had been smoking ranged from at least 1 year4,29 to at least 10 years.28 The 
inclusion criteria for the ECLAT trial differed in that it did not want to recruit those currently attempting to quit 
smoking or wishing to do so in the next 30 days. However, the same trial placed advertisements in a local 
newspaper inviting participants to try e-cigarettes to reduce the risk of tobacco smoking.5 Hatsukami 2019 also 
excluded people if they were planning to quit smoking in the next three months.29 The criteria on prior use of 
smoking cessation aids were variable; however, most trials excluded participants who were currently using 
cessation treatments or had recently used them (see Table 7). 
Table 7 Eligibility criteria regarding smoking history from included RCTs 




Length of time 
smoking 
Intention to quit smoking 
Prior use of smoking cessation 
aids 
ASCEND4 ≥10 At least 1 year Those who wanted to stop 
smoking 
Excluding those using 
cessation drugs 
ECLAT5 ≥10 At least 5 years Those not currently attempting 
to quit smoking or wishing to 
do so in the next 30 days 
Use of smokeless tobacco or 
NRT (no time frame given) 
TEC24 – – – No strong preference to use or 
not to use NRT or e-cigarettes, 
and were currently not using 
either type of product 
Halpern 
201830 
– – – – 
Lee 201925 ≥10 At least 3 years Those who were motivated to 
stop smoking entirely or to 
reduce their cigarette 
consumption 
Excluded those who had 
attempted to stop smoking in 
the past 12 months by using 
other NRTs 
BETOFREE28 ≥10 At least 10 years Those with a high motivation 
to stop smoking 




≥10  - Intention to quit was not an 
inclusion criterion for this 
study 
Included those not currently 
using an e-cigarette, or not 
having used one for more than 
2 days in the last 30 days 
Hatsukami 
201929 
≥5 At least 1 year Excluded if planning to quit 
smoking in the next 3 months 
Excluded those currently using 
NRT or cessation medication 
Lee 201826 >2 - - Excluded those who were 
currently using smoking 
cessation pharmacotherapy or 






6.2 Baseline characteristics 
The sociodemographic characteristics of participants are given in Table 8. Five studies recruited participants 
aged 40–50 years.4,5,24,25,27,29,30 The BETOFREE trial and Lee 2018 involved slightly older patients.28 The majority 
of participants were male.  
The smoking characteristics of the RCT participants were also extracted (see Table 9). Most participants began 
smoking in their teens. Generally, the RCTs included heavy and dependent smokers, with the exception of 
Halpern 2018, who appeared to include lighter smokers.30 
Table 8 Sociodemographic characteristics of participants in the six RCTs  










Age in years          





- - - - 47 
(-) 















38% 63% 52% 49% 100% 63%  90% 50.8% 
Ethnicity 33% 
Māori 













49% 31% - 30% 61% - - - 41.7% 




- - 40.7% -  - - - - 
Married - - - - 90% - - - - 
IQR: Interquartile range 




Table 9 Smoking characteristics of the RCT participants 
Characteristic ASCEND4 ECLAT5 TEC24 Halpern 
201830 






Age started smoking (years)    









Median (IQR) - - 16 
(14–
18) 
- - - - - - 
Number of years smoking continuously    
Mean (SD) 24.7* 
(-) 
- - - 22 
(8.8) 
- - 32 
(-) 
- 
Median (IQR) - - - 18 
(10–29) 
- - -  - 
Number of cigarettes smoked per day     
Mean (SD) 17.9 
(6.3) 





















54% - - - - - - - - 









- - 90% ever 
tried  





































- - - - - - - 
E-cigarette 
use 
- - 41.5% 34% - - - - - 
Past NRT use - - 74.9% - - - - - - 
*Calculated 
IQR: Interquartile range 
FTND: Fagerström Test for Nicotine Dependence 
GN-SBQ: Glover-Nilsson Smoking Behavioral Questionnaire 





The main intervention tested was e-cigarettes with nicotine (ENDS). An overview of the intervention and 
comparators from each of the nine RCTs is presented in Table 10. The mg of nicotine in the intervention e-
cigarettes varied from 0.01 mg/mL to 48 mg/mL. A mix of comparators was reported: nicotine replacement 
therapies, ENNDS (no nicotine), and no additional treatment. For this systematic review the two e-cigarette 
arms of the ECLAT trial have been pooled (see Section 6.7.2 for further explanation of treatment pooling).5 
Two of the trials had a 1-week lead-in period before the agreed quit date,4,28 and one had a 2-week lead-in 
period.29 Five trials had a 12-week treatment period4,5,24,25,28, one had a 6-week treatment period,26, one had 
an 8-week treatment period,29, one had a 24-week treatment period,30 and one had a treatment period up to 
26-weeks.27 
However, it should be noted that in all of the studies, participants were free to purchase further treatments 
after the trial treatment period had ended.  One trial asked participants to sign a commitment not to use the 
non-assigned treatment for at least 4 weeks after their quit date.24 
Concomitant treatments are also presented in *For the purposes of this systematic review and NMA these 
treatment doses have been pooled 
**In this study participants were able to select their preferred nicotine strength from 0mg/mL to 18mg/mL, 
however, none of the participants opted for the lowest concentration option. The most frequently selected 
nicotine strengths were 12 mg/ml and 18 mg/ml, selected by over half of participants. 
*For the purposes of this systematic review and NMA these treatment doses have been pooled 
**In this study participants were able to select their preferred nicotine strength from 0mg/mL to 18mg/mL, 
however, none of the participants opted for the lowest concentration option. The most frequently selected 
nicotine strengths were 12 mg/ml and 18 mg/ml, selected by over half of participants. 
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Table 11; apart from one trial,5 smoking cessation counselling was provided with both the intervention and 
comparator(s).  
The cost of treatment to participants is presented in Table 12. In the Holliday 2019 trial, the trial authors 























10–16 mg/mL NRT patches 21 mg/24 
hours 
ENNDS – 




















ENNDS 0 mg nicotine 
TEC24  E-cigarette starter 
pack: One Kit 
(Aspire) 













NJOY e-cigarettes 10-15 mg/mL No additional 
treatment 







































NJOY e-cigarettes 24-45mg/mL NRT patches 
(Nicoderm) 
14-21mg - - 
*For the purposes of this systematic review and NMA these treatment doses have been pooled 
**In this study participants were able to select their preferred nicotine strength from 0mg/mL to 18mg/mL, 
however, none of the participants opted for the lowest concentration option. The most frequently selected 
nicotine strengths were 12 mg/ml and 18 mg/ml, selected by over half of participants. 
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Table 11 Time on treatment, and concomitant treatment 
Study ID Prior to quit date Post quit date Concomitant treatment 
ASCEND4 1 week 12 weeks Phone or text-based support 
ECLAT5 – 12 weeks None 




– 24 weeks Access to information regarding the 
benefits of smoking cessation and to a 
motivational text messaging service  
Lee 201925 – 12 weeks 50-minute education sessions on smoking 
cessation and the use of smoking cessation 
aids. The participants were asked to visit 
the medical office every 4 weeks for 
evaluation and counselling by an 
independent health practitioner. 
BETOFREE28 1 week 11 weeks Low-intensity telephone counselling at 
weeks 1, 4, 8, and 12 
Holliday 
201927 
- Up to 26 weeks Advice from dentist and option for referral 
to the ‘Newcastle Stop Smoking’ services 
Hatsukami 
201929 
2 weeks 8 weeks Brief counselling on how to avoid smoking 
cigarettes 
Lee 201826 - 6 weeks  All participants received brief counselling 
by the research team, a brochure produced 
by the American Society of 
Anaesthesiologists explaining the benefits 
of preoperative smoking cessation, and a 
referral to the California Smokers' Helpline. 
 
Table 12 Cost of intervention to participants 
Study ID Cost to participants 
ASCEND4 The e-cigarettes were couriered to participants, and those allocated to the patch arm of the study 
were mailed a voucher to exchange for NRT at a pharmacy, and received a separate voucher to 
cover the dispensing costs. 
ECLAT5 None 
TEC24 In the e-cigarette group, participants were asked to purchase their future e-liquid online or from 
local vape shops and to buy a different e-cigarette device if the one supplied did not meet their 
needs. Initially, participants were given only one 30 mL bottle of e-liquid. They were encouraged to 
experiment with e-liquids of different strengths and flavours. Those who were unable to obtain their 
own supply were provided with one additional 10 mL bottle, but this was not offered proactively. 
Halpern 201830  In relevant groups, e-cigarettes and NRT (patches, gum, and lozenges) could be ordered directly 
through the trial website at no cost. Costs of prescription medicines obtained through a physician 
were reimbursable through the trial website. Use of all products was free until 6 months after the 
quit date. 
Lee 201925 None 
BETOFREE28 None 
Holliday 201927 Participants in the ENDS group were provided with an approximately 2-week supply of e-liquid (with 
a choice of flavour and nicotine strength) and information on where to buy more. 
Hatsukami 201929 None 
Lee 201826 None 
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6.4 Efficacy of intervention 
6.4.1 Smoking cessation at 24 or 26 weeks 
Seven included trials reported smoking cessation results at 24 or 26 weeks and the trial-level results are 
presented in Table 13.  
Three studies compared ENDS with NRT,4,24,25 and only one of these RCTs found a statistically significant 
difference in smoking cessation incidence for ENDS versus NRT.24 
Three studies compared ENDS with a ENNDS (no nicotine).4,5,28 None of these trials found a statistically 
significant difference between ENDS and ENNDSs for smoking cessation at 24 or 26 weeks.  
Three studies compared ENDS with no additional treatment,27,28,30 and one of these studies found a 
statistically significant difference in favour of ENDS.30 
Absolute quit rates were ranged greatly across the studies from 0%30 to 35%. 24 
Table 13 RCT results with smoking cessation at 24 or 26 weeks 






Verified  Comparison RR LCI UCI p-
value 
ASCEND4 ENDS 21 289 7% Yes – 1 – – – 
ASCEND4 NRT 17 295 6% Yes ENDS vs NRT 1.26 0.68 2.34 0.46 
ASCEND4 ENNDS 3 73 4% Yes ENDS vs 
ENNDS 
1.77 0.54 5.77 0.44 
ECLAT5 ENDS 22 200 11% Yes – 1 – – – 
ECLAT5 ENNDS 5 100 5% Yes ENDS vs 
ENNDS 
2.20 0.86 5.64 0.10 
TEC24  ENDS 155 438 35% No* – 1 – – – 
TEC24  NRT 112 446 25% No* ENDS vs NRT 1.40 1.14 1.72 – 
Halpern 
201830 






1 813 0% Yes ENDS vs no 
additional 
treatment 
8.14 1.06 62.46 0.04** 
Lee 201925 ENDS 16 75 21% Yes – 1 – – – 
Lee 201925 NRT 21 75 28% Yes ENDS vs NRT 0.76 0.43 1.34 0.34 
BETOFREE28 ENDS 13 70 19% Yes – 1 – – – 
BETOFREE28 ENNDS 11 70 16% Yes ENDS vs 
ENNDS 




7 70 10% Yes ENDS vs no 
additional 
treatment 
1.86 0.79 4.38 0.16 
Holliday 
201927 






2 40 5% Yes ENDS vs no 
additional 
treatment 
3.00 0.64 13..98 0.16 
*Not verified at this timepoint 
**This study intended to use the Holm method to determine significance, however, we report the unadjusted difference 
here as this is what is extracted for all studies. Using the Holm method, this comparison was not considered significantly 
different. 
RR: Relative risk; LCI: Lower confidence interval; UCI: Upper confidence interval 
30 
6.4.2 Smoking cessation at 52 weeks 
Only three RCTs reported data collected at this timepoint. Each study compared e-cigarettes to a different 
control, and the results are presented in Table 14. One study with 300 participants found that ENDS appear 
more effective than ENNDS (no nicotine) for smoking cessation (RR: 2.75; 95% CI: 0.97–7.76), but the 
difference is not statistically significant.5 One study (N=2,012) shows that ENDS appear more effective than no 
additional treatment (RR: 6.11; 95% CI: 0.33–113.24), but again this difference is not statistically significant.30 
One trial (N=886 participants) shows that ENDS are more effective than NRT (RR: 1.83; 95% CI: 1.30–2.58), and 
this difference is statistically significant.24  
Table 14 RCT results with smoking cessation at 52 weeks 




Verified  Comparison RR LCI UCI p-
value 
ECLAT5 ENDS 22 200 Yes – 1 – – – 
ECLAT5 ENNDS 4 100 Yes ENDS vs 
ENNDS 
2.75 0.97 7.76 0.06 
TEC24  ENDS 79 439 Yes – 1 – – – 
TEC24  NRT 44 447 Yes ENDS vs 
NRT 
1.83 1.30 2.58 <0.001 
Halpern 
201830  






0 813 Yes ENDS vs no 
additional 
treatment 
6.11 0.33 113.24 0.22 
RR: Relative risk 
LCI: Lower confidence interval 
UCI: Upper confidence interval 
  
31 
6.5 Adverse events  
6.5.1 Study definitions of an adverse event 
Only two studies used standardised definitions for the coding of adverse events, and only one of these 
specified the coding guidelines that were followed. The TEC trial defined an adverse event according to the 
Medical Dictionary for Regulatory Activities (MedDRA) coding guidelines.24 The standard terms listed by 
MedDRA are used to classify adverse event data from clinical trials and ad hoc reporting. While the ASCEND 
trial state that adverse events were defined according to international guidelines, they do not state which 
guidelines were used, simply describing that this was in line with the CONsolidated Standards of Reporting 
Trials (CONSORT) 2010 Statement.4 
6.5.2 Adverse events by type 
Studies were checked for reporting of adverse events under the categories recommended by the European 
Medicines Agency, as outlined in Section 3.4.1. All studies except Halpern 201830 describe adverse events, and 
provide data at timepoints of 8 weeks,26,29 12 weeks,25 6 months,4,27,28, or 52 weeks.5,24 
The types of adverse events documented during the RCTs studied are indicated in Table 15, whereby ‘Y’ 
indicates that such an event was specifically monitored for, and ‘N’ indicates that it was not monitored for or 
that mention of this was otherwise omitted from the study publications. For example, while it could be 
assumed that all RCTs in this review examined multiple parameters during adverse event monitoring, in the 
case of the ASCEND trial, there is no specific mention of measurement of vital signs, or of symptoms classed as 
psychiatric, cardiovascular, or pulmonary; only serious adverse events are mentioned.4 In general, ASCEND did 
not disclose any qualitative data on non-serious adverse events. Halpern 2018 did not provide evidence of 
having monitored any adverse event data at all, instead recording biochemical metrics from patient blood and 
urine samples.30 BETOFREE recorded data on six out of seven parameters listed in Table 15; however, they did 
not make reference to monitoring serious adverse events.28 While the TEC trial utilised MedDRA terms for 
recording adverse reactions, the health technology statement associated with the study suggests that adverse 
events were not recorded, and instead an adverse reaction checklist was used. This statement is made despite 
the subsequent listing of adverse events (as adverse reactions), particularly those relating to pulmonary 
health.24  
As the Holliday 2019 trial was carried out in a dental setting, only periodontal and withdrawal adverse events 
were reported.27 
Vital signs monitoring, which included blood pressure, body weight, and heart rate measurements, was only 
specified in three of the six RCTs’ methodologies, specifically ECLAT, Hatsukami 2019 and BETOFREE.5,28,29 
While the monitoring of vital signs could be inferred in Lee 2019 through the requirement for weekly doctor 
visits, it is not explicitly mentioned.25  
Psychiatric symptoms were disclosed in three of the six RCTs, although there was some crossover with 
symptoms pertaining to nicotine withdrawal. Specifically, the BETOFREE trial employed a hospital anxiety and 
depression scale tool in order to assess psychiatric symptoms via a self-reported questionnaire.28 The ECLAT 
study assessed subjective psychiatric symptoms using the Beck Depression Inventory and the Beck Anxiety 
Inventory.5 
All RCTs, except Halpern 2018 and Lee 2018, disclosed information on the monitoring of tobacco withdrawal 
symptoms, although the symptoms that were disclosed varied between the studies. The ECLAT trial described 
their study participants as infrequently reporting symptoms commonly associated with nicotine withdrawal 
(hunger, insomnia, irritability, anxiety, and depression).5 Lee 2019 described the occurrence of headache and 
nausea, stating that these were more commonly experienced in the NRT group.25 The TEC trial described 
nicotine withdrawal symptoms as ‘irritability, restlessness, and inability to concentrate’, where these were 
experienced less frequently in the e-cigarette group than in the NRT group.24 The European Medicines Agency 
guidelines recommend that efforts should be made to show withdrawal and rebound phenomena of the 
intervention being studied as distinct from nicotine withdrawal. The guidelines also recommend that nicotine 
withdrawal symptoms should be separated from craving symptoms and measured with different (validated) 
tools.9 All of the RCTs reporting data on nicotine withdrawal utilised the Fagerström Test for Nicotine 
Dependence. However, it is unclear how distinctions were made between nicotine withdrawal and cravings. 
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The ECLAT trial and the Hatsukami 2019 trial also employed the Minnesota Nicotine Withdrawal Scale, which is 
recommended in the European Medicines Agency guidelines.5,9,29 
Participants in the e-cigarette treatment arms of the BETOFREE trial experienced burning throat symptoms 
(following use of both the placebo and nicotine-containing e-cigarettes), with the authors concluding that this 
was possibly related to the use of e-cigarettes and this adverse event increased in frequency of the from 3 to 6 
months.38 
The most consistently reported adverse events were those relating to the pulmonary system, including 
respiratory symptoms relating to smoking, as described in Section 6.5.2.1. 
Table 15 Studies documenting adverse events as recommended by the European Medicines Agency  
Study ID Vital signs Psychiatric Cardiovascula
r 







ASCEND4 N N N N Y 
 
Y 
ECLAT5 Y Y N Y Y Y 
TEC24 N Y Y Y Y Y 
Halpern 
201830  
N N N N N N 
Lee 201925 N N N Y Y Y 
BETOFREE2
8 
Y Y Y Y Y N 
Holliday 
201927 
N N N N Y Y 
Hatsukami 
2019 
Y N N Y N N 
Lee 2018 N N Y Y N Y 
6.5.2.1 Pulmonary adverse events 
Pulmonary events were consistently monitored in six of the nine trials studied (that is, they were mentioned in 
all except Halpern 2018, Holliday 2019 and the ASCEND study). Respiratory symptoms that were noted 
included shortness of breath and cough, as presented in   
33 
Table 16. For all reported adverse events, the incidence was lower in the control arms (NRT or ENNDS [no 
nicotine]), with the exception of shortness of breath in one study28 and cough in one study.24 ASCEND, ECLAT, 
and Lee et al. (2019) did not find that any of the reported pulmonary symptoms were related to treatment, 
but six respiratory events in the TEC study were related to treatment (n=5 in the e-cigarette group and n=1 in 
the NRT group).  
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Table 16 Pulmonary adverse events at endpoint, by symptom and treatment arm  
Symptom Study E-cigarette N 
events 






TEC24 66 64 – 130 
 ECLAT5 12 – 5 17 
 Lee 201925 – – – – 
 BETOFREE28 92  103 106 301 
      
Cough TEC24 97 111 – 208 
 ECLAT5 26 – 11 37 
 Lee 201925 3 3 – 6 
 BETOFREE28 54 50 36 140 
 Hatsukami 2019 15 0 - 15 
 Lee 2018 8 1 - 9 
6.5.3 Serious adverse events 
A serious adverse event was taken to mean any event where a trial participant died or experienced life-
threatening illness or conditions necessitating a hospital stay, as described in the ASCEND trial.4 Although four 
of the six trials detailed the measurement of outcomes relating to serious adverse reactions and two reported 
serious adverse events, no incidence of these events were directly related to the treatment product. Serious 
adverse events that occurred during the ASCEND study included death (n=1, nicotine e-cigarette group), life-
threatening illness (n=1, nicotine e-cigarette group), and various serious conditions requiring hospitalisation.4 
The TEC trial documented serious adverse events in both the nicotine e-cigarette group (n=27) and the NRT 
group (n=22), whereby two of these were deaths: one was due to spinal injury (NRT group) and the other was 
due to ischaemic heart disease (e-cigarette group).24 ECLAT, Holliday 2019, Lee 2018, and Lee 2019 stated that 
no serious adverse events occurred during the course of these studies.5,25-27 ECLAT describe their study’s 
experience of serious adverse events as “no serious adverse events (i.e. major depression, abnormal behaviour 
or any event requiring [an] unscheduled visit to the family practitioner or hospitalisation) occurred during the 
study”.5(P8) Hatsukami 2019 did not mention serious adverse events at all.29 
6.5.4 How treatment correlation was assessed 
Adverse events can occur independently of treatments, but only the ASCEND and TEC trials documented how 
distinctions were made, with the latter only doing so in the case of serious adverse events.4,24 One of the 
authors of the ASCEND study categorised adverse events as being serious or non-serious, and related or 
unrelated to treatment. According to Bullen et al., this was done by association with study treatment in line 
with best practice, comparing incidence rates between groups, where six instances of adverse events were 
found to be related to nicotine e-cigarettes, six were related to NRT, and two were related to ENNDS (no 
nicotine) treatment. In the case of the TEC study, it is unclear how Hajek et al. made decisions regarding 
correlation with treatment. However, it was noted by the trial authors themselves that the serious adverse 
events did not occur as a direct result of the study.   
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6.6 Risk of bias 
We assessed studies for a risk of bias using the Cochrane RoB2 tool.11 As Lee 2018 and Hatsukami 2019 have 
only been included in this systematic review for adverse events, they were analysed for the risk of bias 
associated with reporting of adverse events only.26,29 All other studies were assessed for the risk of bias 
associated with the reporting of cessation outcomes. The risk of bias assessment is summarised in Figure 3 and 
a full explanation of the assessment of each study for each criterion is given in Appendix D. Of the included 
nine RCTs, eight were at a high risk of bias. 
 
Figure 3 Risk of bias in ENDS trials 
The methods used to handle missing data and the numbers of participants lost to follow-up are key 
components of the risk of bias assessment and this information is reported for each study in Table 17. The 
numbers lost to follow-up were high in all of the RCTs, and as the number of cessation events were low in the 
RCTs, this introduces uncertainty to this systematic review. The TEC trial was the only included study which 
attempted to assess the impact of missing data in the four sensitivity analyses described in Table 17. We were 
unable to definitively determine if the RCTs included in this systematic review were industry funded. 
Table 17 Missing data and lost to follow-up in ENDS RCTs 
 Study ID How was missing data 
handled? 
Number lost to follow-
up/discontinued at 6 months 
Number lost to follow-
up/discontinued at 12 months 
ASCEND Assumed participants with 
missing smoking status were 
smoking 
22% in ENDS, 27% in NRT and 
22% in ENNDS arm 
 
ECLAT Assumed that all those 
individuals who were lost to 
follow-up are classified as 
failures 
- 35% in ENDS group A, 37% in 
ENDS group B and 45% in 
nicotine e-cigs group 
Halpern 
2019 
Persons with incomplete 
follow-up data classified as 
smokers 
This trial does not clearly report 
loss to follow-up although it is 
clear there was a very large drop-
out rate. The study authors 
defined an engaged cohort as 
those who had logged on to the 
trial website at least once. ENDS 
were only available through 
logging onto the website so 
those who were not 'engaged' in 
the e-cigarette group received no 
treatment. In the usual care 
- 
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 Study ID How was missing data 
handled? 
Number lost to follow-
up/discontinued at 6 months 
Number lost to follow-
up/discontinued at 12 months 
group 15.9% were engaged and 
21.1% of the e-cigarette group 
were engaged 
Lee 2019 Method for imputing missing 
data not reported 
5.3% in the ENDS group and 
18.6% in the NRT group 
- 
TEC To assess the effect of missing 
data on the primary outcome, 
the authors conducted four 
prespecified sensitivity 
analyses, which excluded 
participants who did not attend 
at least one behavioral-support 
session, excluded participants 
who used the non-assigned 
product for at least 5 
consecutive days, excluded 
participants who did not 
complete the 52-week follow-
up, and imputed missing 
information with the use of 
multiple imputation by chained 
equations. Missing data were 
imputed for 136 participants in 
each group, and 50 data sets 
were imputed 
19.8% in the ENDS group and 
24.6% in the NRT group 
18.9% in the ENDS group and 
23.5% in the NRT group 
BETOFREE Method for imputing missing 
data not reported 
25.7% in the ENDS group, 27.1% 
in the NRT group and 25.7% in 





Participants with missing 
smoking outcome data (e.g. 
those not attending for review) 
were considered as continuing 
smokers or to have resumed 
smoking 
27.5% in both groups - 
Hatsukami 
2019 
Unclear how missing data 
handled for adverse events 
At eight weeks there was 23.7% 
dropout rate in the ENDS arm 
and 30.3% in the NRT arm 
- 
Lee 2018 Unclear how missing data 
handled for adverse events 
20% at eight weeks in NRT and 
10% for ENDS 
- 
 
6.7 Feasibility assessment for meta-analysis 
We carried out an assessment of the feasibility of the network meta-analysis (NMA) following published 
guidance.39,40 Adverse event data were not consistently reported and therefore we were unable to meta-
analyse adverse event results; therefore the two studies that only reported adverse event data of interest are 
not discussed in this section.26,29 
6.7.1 Comparability of populations 
The comparability of populations was considered based on the data presented in Sections 5 and 6.2. The study 
populations of the identified RCTs were considered comparable for pooling. One possible outlier population 
was that involved in the Halpern et al. 2018 trial, which may have involved light smokers, and therefore we 
have conducted a sensitivity analysis excluding this trial from the NMA.30  
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6.7.2 Treatments considered in the network meta-analysis 
The feasibility analysis also considered the main intervention, which was the type of e-cigarette and dosage of 
nicotine given to the participants (see Table 10). Only first- and second-generation e-cigarettes were included 
in the six studies. Electronic nicotine delivery systems (ENDS) was the intervention in all trials, and it was 
compared against NRT single or combination treatments, ENNDS (no nicotine), or no additional treatment. The 
nicotine dose in ENDS arms ranged between 5.4mg/mL and 18mg/mL with the exception of the Lee 2019 trial 
which reported a dose of 0.01mg/mL.25 This study was excluded from the network meta-analysis (NMA) in a 
sensitivity analysis. The studies used different brands of e-cigarettes with variable nicotine content. Two 
studies by Dawkins et al. suggest that using a lower nicotine dose in e-cigarettes may be associated with 
compensatory behaviour, such as increasing the number of puffs and the duration of the puffs in order to 
increase nicotine consumption.41,42 Soar et al. concluded that there may be little benefit in giving lower doses 
of nicotine in e-liquids, as it appears to result in a higher e-liquid consumption.43 These studies suggest that, in 
reality, the nicotine dose will be titrated by the user in order to achieve their preferred consumption level and 
that the dose of nicotine is less important. This evidence supports the pooling of nicotine doses in this NMA. 
All ENDS were grouped together as one treatment intervention for the purposes of the NMA, as outlined in 
Table 18, and one sensitivity analysis for low dose nicotine was carried out.  
The broadest definition of an NRT comparator arm was that of the TEC trial, which allowed an NRT of the 
participants’ choice, including product combinations.24 We therefore grouped all NRT treatments together for 
the purposes of the NMA, as we did for ENDS. This is a limitation of the analysis as previous research has 
suggested that single NRT is not as effective as combination NRT.7 
We considered all ENNDS (without nicotine) to be the same, and usual-care arms (which generally consisted of 
advice and counselling) were labelled as ‘no add’ for the NMA. All treatment group labels are given in Table 18. 
Table 18 Treatment grouping and labels in the network meta-analysis 
Label Treatment group 
ENDS Electronic nicotine delivery systems (e-cigarettes with varied doses of nicotine) 
ENNDS ENNDS (e-cigarettes without nicotine) 
NRT Nicotine replacement therapy including combinations (all types of nicotine replacement therapy, e.g. 
patches, gum, and spray, are considered equivalent) 
No add Only usual care is given in these study arms 
6.7.3 Risk of bias 
The HRB considered conducting a sensitivity analysis excluding the trials at high risk of bias. However, as six of 
the seven included cessation RCTs were at high-risk of bias this was not possible.  
6.7.4 Endpoints and networks 
The number of studies reporting smoking cessation at the timepoints of interest is presented in Table 19. All 
seven RCTs reported smoking cessation results at 24 or 26 weeks. Six of the seven RCTs verified the self-
reported data with biochemical analysis.4,5,25,27,28,30 A sensitivity analysis was conducted that excluded the TEC 
trial, which did not verify the self-reported data at 24 or 26 weeks.24 
Three trials5,24,30 measured smoking cessation at 52 weeks and were included in the 52-week NMA. However, 
we were unable to run an analysis for smoking cessation at the 52-week timepoint, as the model would not 
converge. This was the case even after the number of iterations was increased to 500,000. Lin et al.44 have 
acknowledged that this is a limitation of arm-based models, which may not converge well if some treatments 
are only included in a few studies. This was likely the case here, as Table 19 shows that there were only three 




Table 19 Report of smoking cessation data at timepoints of interest 
Study ID 24- or 26-week follow-up 52-week follow-up 
ASCEND4 ✓  
ECLAT5 ✓ ✓ 
TEC24 ✓ ✓ 
Halpern 201830 ✓ ✓ 
Lee 201925 ✓  
BETOFREE28 ✓  
Holliday 201927 ✓  
 
6.7.5 Summary of analyses 
Based on the results of the feasibility assessment, we elected to carry out the following analyses: 
• An NMA of smoking cessation at the 24 or 26-week timepoint with all seven studies 
• Three sensitivity analyses: 
o One excluding a trial with lighter smokers (Halpern et al. 2018 trial30) 
o One excluding unverified data (TEC trial24) 
o One excluding a low dose nicotine trial (Holliday 201927) 
• A narrative summary of smoking cessation at 52 weeks, as there are insufficient data to conduct an NMA 
or indirect treatment comparison. 
6.7.6 Heterogeneity  
The baseline quit rates (i.e. for the comparator arms) across the trials was highly variable (see Table 13); for no 
additional treatment quit rates ranged between 0%30 to 10%28, for NRT quit rates ranged from 6%4 to 28%25 
and for ENNDS quit rates ranged from 4%4 to 16%28. This suggests that there is underlying heterogeneity in 
study design between the RCTs. 
The effect of heterogeneity on the NMA will be investigated in the sensitivity analyses described in section 
6.7.5. A random effects model has also been chosen for the NMA rather than a fixed effects model as a fixed 
effects model disregards heterogeneity.18 Statistical heterogeneity and observed heterogeneity in e-cigarette 
type and nicotine dose was detected and therefore the random effects NMA model is the most appropriate 
model to use.  
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7 Network meta-analysis of smoking cessation  
7.1 Network meta-analysis and sensitivity analysis at 24 or 26 weeks 
All seven RCTs4,5,24,25,27,28,30 reporting cessation data were included in the 24 or 26-week smoking cessation 
network meta-analysis. 
Figure 4 presents the data and network relationship using the seven RCTs that measured smoking cessation at 
24 or 26 weeks. The majority of the data compare e-cigarettes containing nicotine (ENDS) to NRT, followed by 
ENDS being compared with e-cigarettes without nicotine (ENNDS).  
 
Figure 4 Evidence network for smoking cessation at 24 or 26 weeks 
Using NRT as the reference treatment, the incidence of smoking cessation at 24 or 26 weeks is very similar in 
both the ENDS and the NRT groups (RR: 1.17; 95% CrI: 0.61–1.99), which indicates there is no evidence for a 
difference in effect (see Figure 5). ENNDS (no nicotine) is somewhat less effective in achieving smoking 
cessation than NRT (RR: 0.649; 95% CrI: 0.24–1.42), but the credible intervals are wide, and the result is not 
statistically significant. NRT is more effective than no additional treatment and this result is statistically 
significant (RR:0.35; 95% CrI: 0.11-0.88). The full output of the NMA from gemtc including, the model fit (Dbar, 
pD and DIC) is given in Appendix E. 
40 
 
Figure 5 Network meta-analysis of smoking cessation at 24 or 26 weeks  
7.2 Sensitivity analysis 1: excluding Halpern et al. 2018 trial data 
We conducted a sensitivity analysis to assess the impact of the Halpern et al. 2018 trial, which appears to have 
included lighter smokers.30 In the sensitivity analysis, Halpern et al. (2018) was excluded from the network, 
and the revised evidence network plot is presented in Figure 6. This network plot shows that, with the 
exclusion of the Halpern et al. 2018 trial data, there is less evidence informing the ENDS versus no additional 
treatment comparison. 
 
Figure 6 Evidence network for smoking cessation sensitivity analysis 1 
 
When we removed Halpern et al. (2018)30 from the network, the comparison of incidence rates of smoking 
cessation, at 24 or 26 weeks, for ENDS versus NRT, did not change when compared with the main analysis (RR: 
1.17; 95% CrI: 0.65–1.86, versus RR: 1.17; 95% CrI: 0.60–1.98), (see Figure 7). The comparison of incidence 
rates of smoking cessation at 24 or 26 weeks for ENNDSs (no nicotine) versus NRT also remained similar to the 
main analysis (see Figure 7). In this sensitivity analysis, NRT still appears more effective than no additional 
treatment but there is much greater uncertainty in this estimate. This sensitivity analysis indicates that the 
main analysis is robust to assumptions relating to the smoking history of participants. 
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Figure 7 Network meta-analysis of smoking cessation at 24 or 26 weeks: sensitivity analysis 1 
7.3 Sensitivity analysis 2: excluding unverified data  
We conducted a sensitivity analysis to assess the impact of including unverified data in the analysis. We 
excluded data for the TEC trial24 from the network, as the authors did not verify self-reported smoking 
cessation at the 24- or 26-week timepoint. The revised network plot is presented in Figure 8. This network plot 
shows that, with the exclusion of the TEC trial data, there is less evidence informing the ENDS versus NRT 
comparison. 
 
Figure 8 Evidence network for smoking cessation sensitivity analysis 2 
 
When we removed the TEC trial24 from the network, the point estimate of the relative risk of smoking 
cessation at 24 or 26 weeks for ENDS versus NRT shifted below one, but there is still considerable uncertainty 
in this analysis (RR: 0.93; 95% CrI: 0.41–2.19, versus RR: 1.17; 95% CrI: 0.60–1.98), indicating there is no 
evidence for a difference in effect (see Figure 9). The incidences of smoking cessation at 24 or 26 weeks for 
ENNDS (no nicotine) versus NRT remained similar to the main analysis (see Figure 9). This sensitivity analysis 
indicates that the smoking cessation main analysis results are only marginally influenced by the inclusion of 




Figure 9 Network meta-analysis of smoking cessation at 24 or 26 weeks: sensitivity analysis 2 
7.4 Sensitivity analysis 3: excluding low dose nicotine study 
We conducted a sensitivity analysis to assess the impact of including unverified data in the analysis. We 
excluded data for the Lee 2019 trial25 from the network, as the study assigned participants to a very low dose 
of nicotine. The revised network plot is presented in Figure 10. This network plot shows that with the exclusion 
of the Lee et al. 2019 trial data, there is less evidence informing the ENDS versus NRT comparison. 
 
Figure 10 Evidence network for smoking cessation sensitivity analysis 3 
 
When we removed the Lee 201925 from the network, the point estimate of the relative risk of smoking 
cessation at 24 or 26 weeks for ENDS versus NRT shifted slightly to the right (RR: 1.35; 95% CrI: 0.65–2.60 
versus RR: 1.17; 95% CrI: 0.60–1.98), but the credible intervals are similar indicating there is no evidence for a 
difference in effect (see Figure 11). The incidences of smoking cessation at 24 or 26 weeks for ENNDSs (no 
nicotine) versus NRT remained similar to the main analysis (see Figure 11). This sensitivity analysis indicates 
that the smoking cessation main analysis results are marginally influenced by the inclusion of the low dose 




Figure 11 Network meta-analysis of smoking cessation at 24 or 26 weeks: sensitivity analysis 3 
 
7.5 Inconsistency assessment 
Treatment effects were estimated using both consistency and inconsistency model to determine whether the 
assumption of consistency has an impact on the relative risks estimated by the NMA. The consistency and 
inconsistency models produced very similar estimates of treatment effect, agreeing in terms of direction and 
magnitude of effect. The Deviance Information Criterion (DIC) was marginally lower for the consistency model 
(27.2 versus 28.9). Therefore, the consistency model was considered appropriate.  
Table 20 shows the contribution of direct and indirect evidence to treatment effect estimates. There is 
statistical heterogeneity in the direct estimate for the comparison ENDS versus NRT I2 = 49%. Given this 
measure of heterogeneity and the observed heterogeneity in the RCTs as described in section 6.7 we present 
random effects model data in Table 20. Direct estimates are either taken directly from the study or taken from 
a separate meta-analysis of the direct evidence only. There was no difference in the direction of effect, from 
the direct and indirect evidence, for any of the comparisons. For almost all comparisons, the direct and 
indirect treatment effects were in agreement in terms of magnitude. For the ENDS versus no additional 
treatment comparison, there is greater uncertainty in treatment effect estimate from the NMA random effects 
models compared with the direct estimate., this is probably due to difference in weighting and variance 
estimation methods between the meta-analysis and NMA models. The individual RCTs that directly compared 
these treatments, reported uncertain treatment effects,27,28,30 and so the NMA treatment effect estimate is 
considered reflective of the trial data.  
There is no evidence of inconsistency in the treatment effects presented in this report. 
Table 20 Comparison of direct and indirect treatment effect estimates 
Comparison Number of studies 
informing this comparison 
Direct estimate from study or 
random effects meta-analysis 
95% CI 
NMA estimate from 
random effects model 
95% CrI 
ENDS versus NRT 3 1.18 (0.82 – 1.68) 1.17 (0.61 – 1.99) 
ENNDS versus NRT 1 0.71 (0.21 – 2.37) 0.65 (0.24 – 1.42) 
No additional 
treatment versus NRT 
0 No direct evidence 0.35 (0.11 – 0.88) 
ENDS versus no 
additional treatment 
3 2.45 (1.21 – 4.94) 3.32 (1.51 – 8.88) 
ENNDS versus no 
additional treatment 
1 1.57 (0.65 – 3.82) 1.86 (0.70 – 5.47) 
ENDS versus ENNDS 3 1.54 (0.92 – 2.59) 1.79 (0.91 – 3.90) 
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8 Discussion  
From an initial 1,396 studies, 11 RCTs reported in 19 publications met the inclusion criteria for this systematic 
review; two RCTs for heat-not-burn tobacco products and nine for ENDS.  
8.1 Summary of e-cigarette trials 
Nine RCTs4,5,24-30 reported in 15 publications met the inclusion criteria for efficacy (N=7) and safety ( N=9) of e-
cigarettes in helping people who smoke to achieve abstinence (smoking cessation). NRT is the treatment that 
is currently used in Ireland,7,10 and therefore, comparisons have been made to this reference treatment. Two 
trials reported safety data only. The number of participants in the RCTs ranged from 30 to 2,012. Of the nine 
trials, two were based in Italy, three in the USA, two in the UK, and one each was based in South Korea, and 
New Zealand. On average, participants in the included RCTs were males aged 40–50 years who were depedent, 
heavy smokers. One trial appeared to include lighter smokers, and the influence of this trial on the network 
meta-analysis was examined through a sensitivity analysis.  
ENDS was the intervention in all trials, and it was compared to NRT in single or combination treatments, 
placebo e-cigarettes (ENNDS), and/or no additional treatment. First and second-generation ENDS devices were 
used. The nicotine dose in cessation studies ranged from 5.4mg/mL to 18mg/mL, except for the Lee 2019 trial 
which reported a dose of 0.01mg/ mL. This study was excluded from the network meta-analysis in a sensitivity 
analysis. The two studies included for safety data only allowed participants to have nicotine doses of 24-
48mg/mL.26,29 
Smoking cessation data reported at 24 or 26 weeks and 52 weeks were included. Self-reported data, which 
was then chemically verified, was preferred over self-reported only, and unverified data was excluded in a 
sensitivity analysis to test its impact on the overall meta-analysis results.  
8.2 Summary of heat-not-burn tobacco product trials 
This systematic review identified very limited data on the efficacy and safety of heat-not-burn tobacco 
products; no RCTs were found to report cessation results at the 6 or 12 month timepoints of interest and only 
two RCTs reported adverse event data.31,32 No conclusions could be reached from these data and further 
research is needed if these tobacco products are to be considered as a smoking cessation tool. 
8.2.1 Risk of bias 
The HRB carried out a risk of bias analysis using the Cochrane RoB 2 tool for randomised trials. Of the included 
nine RCTs, eight of these were at a high risk of bias. This rating is mainly driven by missing outcome data. The 
numbers lost to follow-up were high in all of the RCTs, and as the number of successful cessation events was 
low in the RCTs, this introduces uncertainty to this systematic review. The TEC trial using four sensitivity 
analyses was the only included study which assessed the impact of missing data .24 
8.2.2 Smoking cessation 
The network meta-analysis of smoking cessation at 24 or 26 weeks is based on seven RCTs. Using NRT as the 
reference treatment, the incidences of smoking cessation at 24 or 26 weeks are very similar in both the ENDS 
and the NRT groups (RR: 1.17; 95% CrI: 0.61–1.99) and this indicates there is no evidence of a difference in 
effect. ENNDS (no nicotine) is somewhat less effective in achieving smoking cessation than NRT (RR: 0.649; 
95% CrI: 0.24–1.42), but the result is not statistically significant. NRT is more effective than no additional 
treatment and this result is statistically significant (RR:0.35; 95% CrI: 0.11-0.88). Three sensitivity analyses 
were carried out: the first excluded the RCT which appeared to include lighter smokers, the second included 
only those RCTs which had biochemically verified their smoking data, and the third excluded the study with a 
lower dose of nicotine for the ENDS arm. The results of these sensitivity analysis indicate that the main 
analysis is robust to assumptions relating to the smoking history of participants and inclusion of unverified 
data, and slightly less robust to the assumption of nicotine dose.  
As indicated in the feasibility assessment, we were unable to undertake a network meta-analysis of smoking 
cessation at 52 weeks due to limited data; only three RCTs reported data for this timepoint. Each study 
compared e-cigarettes to a different control, and results were mixed. One study with 300 participants found 
that ENDS appears more effective than ENNDSs (no nicotine) for smoking cessation (RR: 2.75; 95% CI: 0.97–
7.76), but the difference is not statistically significant.5 One study shows that ENDS appears more effective 
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than no additional treatment (RR: 6.11; 95% CI: 0.33–113.24), but again this difference is not statistically 
significant.30 One trial (N=886 participants) shows that ENDS is more effective than NRT (RR: 1.83; 95% CI: 
1.30–2.58), and this difference was statistically significant.24 These results are mixed and suggest that further 
long-term large scale study is needed in order to reduce uncertainty around these estimates.  
There is uncertainty for all of these analyses, and it is attributed in part to the low number of successful events 
in each study coupled with the large numbers lost to follow-up. 
8.2.3 Adverse events 
This systematic review found that standardised definitions were not used to record adverse events in all of the 
included studies. Several of the adverse event categories recommended for observation by the European 
Medicines Agency, including the cardiovascular category (where three out of the nine studies reported 
findings) and the psychiatric category (where three out of the nine studies reported findings), were not 
captured systematically.  
Pulmonary events were consistently monitored in six of the nine trials studied (that is, they were mentioned in 
all except Halpern 2018, Holliday 2019 and the ASCEND study). Respiratory symptoms that were noted 
included shortness of breath and cough. For all reported adverse events, the incidence of each was lower in 
the control arms (NRT or ENNDS), with the exception of shortness of breath in one study28 and cough in one 
study.24 ASCEND, ECLAT, and Lee et al. (2019) did not find that any of the reported pulmonary symptoms were 
related to treatment, but six respiratory events in the TEC study were related to treatment (n=5 in the e-
cigarette group and n=1 in the NRT group).  
It should be noted that no serious adverse events were designated as being related to the treatment (e-
cigarettes or its comparators) in the four studies that reported serious adverse events. The procedure for 
determining if a serious adverse event was treatment related was often unclear. 
The adverse events in these studies were all collected over a short period of time (≤12 months), and longer-
term studies are therefore needed in order to fill this data gap. The HRB study findings align with three other 
systematic reviews indicating that the long-term implications of using e-cigarettes are unclear.45-47 
A companion project to this systematic review, also completed by the HRB, mapped the public health harms 
and benefits of e-cigarettes and gives an outline of all the current literature in this area.48 
8.2.4 Level and certainty of evidence 
We assigned a Level 2 evidence rating using the Centre for Evidence-Based Medicine levels of evidence 
guidelines,49 as we had seven RCTs in the network meta-analysis, but six of the seven trials had a high risk of 
bias. With respect to the certainty of evidence,50,51 we believe that there is low certainty of evidence that e-
cigarettes have the same levels of success in achieving smoking cessation as other medically approved (by the 
Health Products Regulatory Authority in Ireland or the European Medicines Agency) cessation interventions 
based on results of the network meta-analysis because of the high risk of bias in six of the seven trials, the low 
number of successful events in the trials, and the high dropout rates. 
There is a very low certainty of evidence that e-cigarettes have the same levels of success in achieving smoking 
cessation as other medically approved cessation interventions, based on three trials, for smoking cessation at 
52 weeks, and therefore results are inconclusive. 
For heat-not-burn tobacco products, there is a very low (or no) certainty of evidence for using these tobacco 
products as a smoking cessation intervention.  
8.3 Comparison with previous research 
The HRB synthesis reveals that e-cigarettes with nicotine may be as effective as NRT in achieving smoking 
cessation at 24 or 26 weeks (seven RCTs). Previous syntheses by Hartmann-Boyce et al. and Rahman et al. 
indicated that there are significant findings from the pooled results of two trials that e-cigarettes with nicotine, 
compared with ENNDSs (no nicotine), helped smokers to stop smoking long term.3,52 On the other hand, a 
2016 review by Kalkhoran and Glatzlost concluded that e-cigarettes are associated with significantly lower quit 
rates among smokers.53 More recent syntheses by El Dib et al.6 and Khoudigian et al.,54 based on two and 
three trials, respectively, report findings similar to ours – that the incidences of smoking cessation at 24 or 26 
weeks for ENDS versus ENNDS indicates that an e-cigarette with nicotine is marginally better than one without 
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nicotine, but that this result is not statistically significant and there is a high level of uncertainty. According to a 
World Health Organisation report, based mostly on a National Academies of Sciences systematic review, some 
types of ENDS aid in smoking cessation, in certain circumstances, but the evidence is insufficient to issue a 
blanket recommendation to use any type of e-cigarette (nicotine or non-nicotine) as a cessation aid for all 
smokers.55 
8.4 Strengths and limitations 
The main strength of this systematic review is that it used a comprehensive search strategy that is likely to 
have captured all relevant trials and that it adds five new trials to the statistical synthesis by Cochrane, leading 
to an updated systematic review of the topic.  
The main limitation of this review is that e-cigarettes are not a standardised intervention. A variety of first- and 
second-generation e-cigarettes were tested, and the nicotine doses varied (see Table 10). As none of the 
studies tested third- or fourth-generation e-cigarettes, the relevance of the analysis is limited.  
Other limitations of this review are the small sample sizes in the examined trials and the low number of 
patients achieving smoking cessation. Seven included RCTs reported smoking cessation at 24 or 26 
weeks,4,5,24,25,27,28,30 and only three of those also reported smoking cessation at 52 weeks.5,24,30 In addition, loss 
to follow-up was very high and exceeded 20% in at least one arm of eight of the nine included trials.4,5,24,26-30  
During the 12-week observation period that followed the active treatment period, participants could purchase 
further smoking cessation therapies; these data were not recorded by most of the trials. One trial asked 
participants to sign a commitment not to use the non-assigned treatment for at least 4 weeks after their quit 
date.24 
The power of the comparisons between the comparator arms of the HRB’s network meta-analysis would have 
been increased if we had widened our inclusion criteria to RCTs examining medically approved cessation 
therapies as well as behavioural therapies that were not compared directly to e-cigarettes. However, our brief 
was to examine the efficacy of e-cigarettes and their contribution to smoking cessation.  
8.5 Conclusion 
The systematic review and network meta-analysis of electronic nicotine delivery systems (e-cigarettes) versus 
therapies usually given for smoking cessation showed that there is no evidence of a difference in effect on 
incidences of smoking cessation. There is a low-level of certainty in these results due to low successful event 
rates and high rates lost to follow-up in all studies.  
The systematic review of evidence for heat-not-burn tobacco products showed that there is no evidence from 
RCTs on efficacy for smoking cessation compared with current standard care, and insufficient evidence on the 
safety of heat-not-burn tobacco products from RCTs. 
Identified respiratory adverse events, including shortness of breath and cough, appeared to be higher in 
electronic nicotine delivery systems users, but in the main, RCT evidence on adverse events is lacking. The 
long-term data on electronic nicotine delivery systems, in line with European Medicines Agency 
recommendations, are limited for both smoking cessation and adverse events, and further large-scale research 
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Appendix A Literature search strategies 
Ovid MEDLINE  
Search date: 27.02.2020 
Database provider: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and 
Versions(R) 1946 to February 26, 2020 
Filter used: Cochrane highly-sensitive RCT filter 
Search 
number 
Search term Results 
1 Vaping/  651 
2 Electronic Nicotine Delivery Systems/  2994 
3 "Nebulizers and Vaporizers"/ and (nicotine or tobacco).mp.  162 
4 e-cig$.mp.  4039 
5 Ecig$.mp.  98 
6 (Vape or vaping or vaper or vapers).mp.  1517 
7 (Vapori#e$ adj3 (cigarette$ or nicotine)).mp.  92 
8 ((electric or electronic) adj2 (cig$ or nicotine or tobacco or smoking)).mp.  4570 
9 (e-sigaret$ or "e-sígarett$" or een sigaret$ or E-Zigarette$ or "cigarette$ électronique$" 
or "L'e-cigarette" or vapoteuse$ or "cigarrill$ electrónico$" or sigarett$ elettronic$ or 
sigarett$ elettronik$ or sigarett$ elettroniche$ or elektronik$ sigar$ or e-savuke$ or e-
rokok$ or rokok$ elektronik$ or e-papieros$ or e-ugwayi).mp.  
72 
10 (mods adj5 (tobacco or nicotine)).mp.  3 
11 Juul$.mp.  97 
12 (e-juice$ or e-liquid$).mp.  521 
13 (cig-a-like$ or cigalike$ or ciga-like$).mp.  48 
14 (e-hookah$ or electronic hookah$ or "hookah pens").mp.  22 
15 (ENNDS or electronic non-nicotine delivery).mp.  4 
16 ((NMNDS and nicotin$) or non-medicinal nicotine delivery system$).mp.  0 
17 or/1-16  5944 
18 (Heated tobacco product$ or tobacco heating product$ or tobacco heating 
system$).mp.  
164 
19 ("heat-not-burn" or "heat not burn" or "heat notburn" or "heatnot burn").mp.  113 
20 (Heatsticks or heat-sticks or tobacco sticks or Neosticks).mp.  17 
21 ((HEETS or Fiit or glo) adj3 (tobacco or nicotine or smok$)).mp.  3 
22 (IQOS or iFuse or Ploom).mp.  94 
23 (electrically-heated smoking system and (nicotin$ or tobacco$)).mp.  1 
24 (Vapotage or "tabac chauffé" or "verhitte tabak" or "riscaldatori di tabacco" or "tabacco 
riscaldato" or "erhitzter Tabak" or "verhit tabak" or "zahřátý tabák" or "opvarmet tobak" 
or "oppvarmet tobakk" or "uppvärmd tobak" or "kuumutatud tubakas" or "pinainit na 
tabako" or "lämmitetty tupakka" or "shan taba mai tsanani" or "hitað tóbak" or 
"apsildāmā tabaka" or "tembakau dipanaskan" or "šildomas tabakas" or "tembakau 
yang dipanaskan" or "te taakapa" or "podgrzewany tytoń" or "tabaco aquecido" or 
"încălzit tutunul" or "zahriaty tabak" or "ogrevani tobak" or "tabaco caliente" or 
"ısıtılmış tütün" or "ugwayi ovuthayo" or "thuốc lá nóng").mp.  
16 




26 17 or 25  6097 
27 ((randomized controlled trial or controlled clinical trial).pt. or (randomized or placebo or 
randomly or trial or groups).ab. or drug therapy.fs.) not exp animals/ not humans.sh.  
520956 
28 26 and 27  344 
 
Cochrane Library 
Search date: 26.02.2020 
Database provider: John Wiley & Son Inc.. Cochrane Library including Cochrane CENTRAL 
ID Search Hits 
#1 MeSH descriptor: [Vaping] explode all trees 21 
#2 MeSH descriptor: [Electronic Nicotine Delivery Systems] explode all trees  89 
#3 MeSH descriptor: [Nebulizers and Vaporizers] explode all trees 2269 
#4 ((nicotine OR tobacco)):ti,ab,kw 12123 
#5 #3 AND #4 32 
#6 (e-cig*):ti,ab,kw 432 
#7 (ecig*):ti,ab,kw 432 
#8 (vape OR vaping OR vaper OR vapers):ti,ab,kw 114 
#9 (((vaporise OR vaporised OR vaporiser OR vaporize OR vaporized OR vaporizer) 
NEAR/3 (cigarette* OR nicotine))):ti,ab,kw 
21 
#10 (((electric or electronic) NEAR/2 (nicotine or tobacco or smoking or cig*))):ti,ab,kw 426 
#11 ((e-sigaret* OR "e-sígarett*" OR E-Zigarette* OR "cigarette* électronique*" OR "L'e-
cigarette" OR vapoteuse* OR "cigarrill* electrónico*" OR sigarett* elettronic* OR 
sigarett* elettronik* OR sigarett* elettroniche* OR elektronik* sigar* OR e-savuke* 
OR e-rokok* OR rokok* elektronik* OR e-papieros* OR e-ugwayi)):ti,ab,kw 
8 
#12 ((mods NEAR/5 (nicotine OR tobacco))):ti,ab,kw 0 
#13 (Juul*):ti,ab,kw 22 
#14 ((e-juic* OR e-liquid*)):ti,ab,kw 72 
#15 ((cig-a-like* OR cigalike* OR ciga-like*)):ti,ab,kw 6 
#16 ((e-hookah* OR "electronic hookah" OR "electronic hookahs" OR "hookah pen" OR 
"hookah pens")):ti,ab,kw 
4 
#17 ((ENNDS OR "electronic non-nicotine delivery")):ti,ab,kw 0 
#18 ((NMNDS AND nicotin*)):ti,ab,kw 0 
#19 ((non-medicinal nicotine delivery system*)):ti,ab,kw 0 
#20 #1 OR #2 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 
OR #15 OR #16 OR #17 OR #18 OR #19 
630 
#21 (("heated tobacco" OR "tobacco heating")):ti,ab,kw  52 
#22 ((Heated tobacco product* OR tobacco heating product* OR tobacco heating 
system*)):ti,ab,kw 
80 
#23 (("heat-not-burn" OR "heat not burn" OR "heat notburn" OR "heatnot burn" OR 
"heatnotburn")):ti,ab,kw 
10 
#24 ((Heatsticks OR heat-sticks OR "heat sticks" OR tobacco sticks OR 
Neosticks)):ti,ab,kw 
11 
#25 ((IQOS or iFuse or Ploom)):ti,ab,kw 25 
#26  ((Vapotage OR "tabac chauffé" OR "verhitte tabak" OR "riscaldatori di 





"zahřátý tabák" OR "opvarmet tobak" OR "oppvarmet tobakk" OR "uppvärmd 
tobak" OR "kuumutatud tubakas" OR "pinainit na tabako" OR "lämmitetty tupakka" 
OR "shan taba mai tsanani" OR "hitað tóbak" OR "apsildāmā tabaka" OR "tembakau 
dipanaskan" OR "šildomas tabakas" OR "tembakau yang dipanaskan" OR "te 
taakapa" OR "podgrzewany tytoń" OR "tabaco aquecido" OR "încălzit tutunul" or 
"zahriaty tabak" OR "ogrevani tobak" OR "tabaco caliente" OR "ısıtılmış tütün" OR 
"ugwayi ovuthayo" OR "thuốc lá nóng")):ti,ab,kw 
#27 ((HEETS or Fiit or glo) NEAR/3 (tobacco or nicotine or smok*)):ti,ab,kw 1 
#28 (("electrically-heated smoking system" AND (nicotin* OR tobacco*))):ti,ab,kw 0 
#29 #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 122 
#30 #20 OR #29 723 
 Of which results, trials: n=709 Reviews excluded 709 
 
Embase.com 
Search date: 26.02.2020 
Filter used: Cochrane highly-sensitive RCT filter for Embase 
1  'vaping'/exp OR 'vaping' 1806 
2 'electronic cigarette'/exp  5,838 
3 'e cig*':ti,ab,kw  4,875 
4 ecig*:ti,ab,kw  275 
5 vape:ti,ab,kw OR vaping:ti,ab,kw OR vaper:ti,ab,kw OR vapers:ti,ab,kw  1,377 
6 vapori?e$ NEAR/3 (cigarette* OR nicotine)  93 
7  ((electric OR electronic) NEAR/2 (cig* OR nicotine OR tobacco OR smoking)):ti,ab,kw  3,988 
8 'e sigaret*':ti,ab,kw OR 'e sígarett*':ti,ab,kw OR 'e zigarette*':ti,ab,kw OR 'cigarette* 
électronique*':ti,ab,kw OR 'l e cigarette':ti,ab,kw OR vapoteuse*:ti,ab,kw OR 'cigarrill* 
electrónico*':ti,ab,kw OR 'sigarett* elettronic*':ti,ab,kw OR 'sigarett* elettronik*':ti,ab,kw 
OR 'sigarett* elettroniche*':ti,ab,kw OR 'elektronik* sigar*':ti,ab,kw OR 'e 
savuke*':ti,ab,kw OR 'e rokok*':ti,ab,kw OR 'rokok* elektronik*':ti,ab,kw OR 'e 
papieros*':ti,ab,kw OR 'e ugwayi':ti,ab,kw  
13 
9  (mods NEAR/5 (tobacco OR nicotin* OR smoking OR cigarette)):ti,ab,kw  5 
10 'juul*':ti,ab,kw  117 
11 'e juice*':ti,ab,kw OR 'e liquid*':ti,ab,kw 737 
12 'cig-a-like*':ti,ab,kw OR 'cigalike*':ti,ab,kw OR 'ciga-like*':ti,ab,kw OR 'cig-alike':ti,ab,kw  42 
13 'e hookah*':ti,ab,kw OR 'electronic hookah*':ti,ab,kw OR 'electric hookah*':ti,ab,kw OR 
'hookah pen*':ti,ab,kw OR 'e-shisha':ti,ab,kw OR 'electronic shisha':ti,ab,kw OR 'electric 
shisha':ti,ab,kw  
28 
14 'ennds':ti,ab,kw OR 'electronic non-nicotine delivery':ti,ab,kw  8 
15 nmnds:ti,ab,kw AND nicotine:ti,ab,kw  0 
16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15  
7,553 
17 'heated tobacco':ti,ab,kw OR 'tobacco heating':ti,ab,kw  249 
18 'heat-not-burn':ti,ab,kw OR 'heat not burn':ti,ab,kw OR 'heat notburn':ti,ab,kw OR 
'heatnot burn':ti,ab,kw  
149 
19 'heatsticks':ti,ab,kw OR 'heatstick':ti,ab,kw OR 'heat-stick':ti,ab,kw OR 'heat-
sticks':ti,ab,kw OR 'tobacco sticks':ti,ab,kw OR 'tobacco stick':ti,ab,kw OR 





20  ((heets OR fiit OR glo OR ifuse) NEAR/3 (tobacco OR nicotine OR smok*)):ti,ab,kw  7 
21 iqos:ti,ab,kw OR ploom:ti,ab,kw  96 
#22 'electrically-heated smoking system':ti,ab,kw AND (nicotin*:ti,ab,kw OR 
tobacco*:ti,ab,kw)  
1 
#23 vapotage:ti,ab,kw OR 'tabac chauffé':ti,ab,kw OR 'verhitte tabak':ti,ab,kw OR 'riscaldatori 
di tabacco':ti,ab,kw OR 'tabacco riscaldato':ti,ab,kw OR 'erhitzter tabak':ti,ab,kw OR 
'verhit tabak':ti,ab,kw OR 'zahřátý tabák':ti,ab,kw OR 'opvarmet tobak':ti,ab,kw OR 
'oppvarmet tobakk':ti,ab,kw OR 'uppvärmd tobak':ti,ab,kw OR 'kuumutatud 
tubakas':ti,ab,kw OR 'pinainit na tabako':ti,ab,kw OR 'lämmitetty tupakka':ti,ab,kw OR 
'shan taba mai tsanani':ti,ab,kw OR 'hitað tóbak':ti,ab,kw OR 'apsildāmā tabaka':ti,ab,kw 
OR 'tembakau dipanaskan':ti,ab,kw OR 'šildomas tabakas':ti,ab,kw OR 'tembakau yang 
dipanaskan':ti,ab,kw OR 'te taakapa':ti,ab,kw OR 'podgrzewany tytoń':ti,ab,kw OR 'tabaco 
aquecido':ti,ab,kw OR 'încălzit tutunul':ti,ab,kw OR 'zahriaty tabak':ti,ab,kw OR 'ogrevani 
tobak':ti,ab,kw OR 'tabaco caliente':ti,ab,kw OR 'ısıtılmış tütün':ti,ab,kw OR 'ugwayi 
ovuthayo':ti,ab,kw OR 'thuốc lá nóng':ti,ab,kw 
2 
24 #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 370 
25 #16 OR #24 7,772 
26 'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled 
trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR factorial*:de,ab,ti OR 
crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR placebo*:de,ab,ti OR ((doubl* 
NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 blind*):de,ab,ti) OR assign*:de,ab,ti OR 






Appendix B List of articles excluded at full text stage  
 Reference Reason for exclusion 
1 Adriaens K, Van Gucht D, Declerck P, et al. Effectiveness of the 
electronic cigarette: An eight-week Flemish study with six-
month follow-up on smoking reduction, craving and 
experienced benefits and complaints. International journal of 
environmental research and public health 2014;11(11):11220-
48. doi: 10.3390/ijerph111111220 [published Online First: 
2014/10/31] 
Control (Participants were allowed 
to continue smoking) 
2 Baldassarri SR, Bernstein SL, Chupp GL, et al. Electronic 
cigarettes for adults with tobacco dependence enrolled in a 
tobacco treatment program: A pilot study. Addictive behaviors 
2018;80:1-5. doi: 10.1016/j.addbeh.2017.11.033 [published 
Online First: 2018/01/06] 
Intervention (NRT given in combo 
with EC) 
3 Chaumont M, Bernard A, Pochet S, et al. High-Wattage E-
Cigarettes Induce Tissue Hypoxia and Lower Airway Injury: A 
Randomized Clinical Trial. American journal of respiratory and 
critical care medicine 2018;198(1):123-26. doi: 
10.1164/rccm.201711-2198LE [published Online First: 
2018/02/17] 
Study design (crossover and short 
duration treatment) 
4 4. Harhay MO, Troxel AB, Brophy C, et al. Financial Incentives 
Promote Smoking Cessation Directly, Not by Increasing Use of 
Cessation Aids. Annals of the American Thoracic Society 
2019;16(2):280-82. doi: 10.1513/AnnalsATS.201808-574RL 
[published Online First: 2018/10/06] 
Intervention (Secondary analysis of 
Halpern trial but only analysing 
effects of monetary intervention) 
5 5. Kumral TL, Salturk Z, Yildirim G, et al. How does electronic 
cigarette smoking affect sinonasal symptoms and nasal 
mucociliary clearance? B-ent 2016;12(1):17-21. [published 
Online First: 2016/04/22] 
Outcomes 
6 6. Lee SM, Tenney R, Wallace A, et al. The end perioperative 
smoking pilot study: A randomized trial comparing e-cigarettes 
versus nicotine patch. Canadian Journal of Anesthesia 
2017;64(1):S48-S49. doi: 10.1007/s12630-017-1003-0 
Study design (conference abstract) 
7 7. Li J, Hajek P, Pesola F, et al. Cost-effectiveness of e-
cigarettes compared with nicotine replacement therapy in 
stop smoking services in England (TEC study): a randomized 
controlled trial. Addiction (Abingdon, England) 
2020;115(3):507-17. doi: 10.1111/add.14829 
Study design 
8 8. Martin F, Talikka M, Ivanov NV, et al. Evaluation of the 
tobacco heating system 2.2. Part 9: Application of systems 
pharmacology to identify exposure response markers in 
peripheral blood of smokers switching to THS2.2. Regulatory 
toxicology and pharmacology : RTP 2016;81 Suppl 2:S151-s57. 
doi: 10.1016/j.yrtph.2016.11.011 [published Online First: 
2016/11/16] 
Intervention (too short treatment 
length) 
 
9 9. Ogden MW, Marano KM, Jones BA, et al. Switching from 
usual brand cigarettes to a tobacco-heating cigarette or snus: 
Part 2. Biomarkers of exposure. Biomarkers : biochemical 
indicators of exposure, response, and susceptibility to 
chemicals 2015;20(6-7):391-403. doi: 
10.3109/1354750x.2015.1094134 [published Online First: 
2015/11/12] 
Control 
10 10. Ogden MW, Marano KM, Jones BA, et al. Switching from 
usual brand cigarettes to a tobacco-heating cigarette or snus: 
Part 3. Biomarkers of biological effect. Biomarkers : 





susceptibility to chemicals 2015;20(6-7):404-10. doi: 
10.3109/1354750x.2015.1094135 [published Online First: 
2015/11/04] 
11 11. Ogden MW, Marano KM, Jones BA, et al. Switching from 
usual brand cigarettes to a tobacco-heating cigarette or snus: 
Part 1. Study design and methodology. Biomarkers : 
biochemical indicators of exposure, response, and 
susceptibility to chemicals 2015;20(6-7):382-90. doi: 
10.3109/1354750x.2015.1094133 [published Online First: 
2015/11/04] 
Control 
12 1. Picavet P, Haziza C, Lama N, et al. Reduced exposure to 
harmful and potentially harmful constituents after 90 days of 
use of tobacco heating system 2.2 in Japan: A comparison with 
continued combustible cigarette use or smoking abstinence. 
Toxicology Letters 2016;259:S141. doi: 
10.1016/j.toxlet.2016.07.597 
Study design (conference abstract) 
13 1. Pravettoni G, Masiero M, Lucchiari C, et al. The role of 
electronic cigarettes in smoking cessation among heavy 
smokers undergoing a lung cancer screening program: 
Preliminary results of a randomized controlled study. Psycho-
Oncology 2016;25:72. doi: 10.1002/pon.4082 





Appendix C Risk of bias in heat-not-burn RCTs 














 Journal article(s) with 






Results   Weight 1 














1.2 Was the allocation 
sequence concealed until 
participants were enrolled 
and assigned to 
interventions? 
NI 
1.3 Did baseline 
differences between 
intervention groups 
suggest a problem with the 
randomization process? 
N   












2.1. Were participants 
aware of their assigned 




intervention was just 
smoking abstinence  
2.2. Were carers and 
people delivering the 
interventions aware of 
participants' assigned 
intervention during the 
trial? 
PY 
2.3. If Y/PY/NI to 2.1 or 
2.2: Were there deviations 
from the intended 
intervention that arose 
because of the 
experimental context? 
NI   
2.4 If Y/PY to 2.3: Were 
these deviations likely to 
have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: 
Were these deviations 
from intended intervention 
balanced between 
groups? 
NA   
2.6 Was an appropriate 
analysis used to estimate 
the effect of assignment to 
intervention? 




2.7 If N/PN/NI to 2.6: Was 
there potential for a 
substantial impact (on the 
result) of the failure to 
analyse participants in the 
group to which they were 
randomized? 
NA   










3.1 Were data for this 
outcome available for all, 
or nearly all, participants 
randomized? 
N 
There was low compliance 
with the protocol  
3.2 If N/PN/NI to 3.1: Is 
there evidence that result 
was not biased by missing 
outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the 
outcome depend on its 
true value? 
NI 
No information is given on 
the large number of non-
compliant participants 
3.4 If Y/PY/NI to 3.3: Is it 
likely that missingness in 
the outcome depended on 
its true value? 
NI 
Risk of bias 
judgement 






4.1 Was the method of 
measuring the outcome 
inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the 
outcome have differed 
between intervention 
groups? 
PN   
4.3 Were outcome 
assessors aware of the 
intervention received by 
study participants? 
PY 
not reported but 
intervention and control are 
so different 
4.4 If Y/PY/NI to 4.3: 
Could assessment of the 
outcome have been 
influenced by knowledge 
of intervention received? 
PY 
  
4.5 If Y/PY/NI to 4.4: Is it 
likely that assessment of 
the outcome was 
influenced by knowledge 
of intervention received? 
NI 
Risk of bias 
judgement 






5.1 Were the data that 
produced this result 
analysed in accordance 
with a pre-specified 
analysis plan that was 
finalized before unblinded 




outcome data were 
available for analysis? 
5.2 ... multiple eligible 
outcome measurements 
(e.g. scales, definitions, 
time points) within the 
outcome domain? 
PN   
5.3 ... multiple eligible 
analyses of the data? 
PN   







Risk of bias 
judgement 
High   
      














 Journal article(s) with 






Results   Weight 1 














1.2 Was the allocation 
sequence concealed until 
participants were enrolled 
and assigned to 
interventions? 
NI 
1.3 Did baseline 
differences between 
intervention groups 
suggest a problem with the 
randomization process? 
N   












2.1. Were participants 
aware of their assigned 
intervention during the 
trial? 
PY 
Not reported but treatments 
are so different 
2.2. Were carers and 
people delivering the 
interventions aware of 
participants' assigned 
intervention during the 
trial? 
PY 
2.3. If Y/PY/NI to 2.1 or 
2.2: Were there deviations 
from the intended 




intervention that arose 
because of the 
experimental context? 
2.4 If Y/PY to 2.3: Were 
these deviations likely to 
have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: 
Were these deviations 
from intended intervention 
balanced between 
groups? 
NA   
2.6 Was an appropriate 
analysis used to estimate 
the effect of assignment to 
intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was 
there potential for a 
substantial impact (on the 
result) of the failure to 
analyse participants in the 
group to which they were 
randomized? 
NA   










3.1 Were data for this 
outcome available for all, 
or nearly all, participants 
randomized? 
Y 
Only 2 people discontinued 
from each group 
3.2 If N/PN/NI to 3.1: Is 
there evidence that result 
was not biased by missing 
outcome data? 
NA   
3.3 If N/PN to 3.2: Could 
missingness in the 




3.4 If Y/PY/NI to 3.3: Is it 
likely that missingness in 
the outcome depended on 
its true value? 
NA 
Risk of bias 
judgement 






4.1 Was the method of 
measuring the outcome 
inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the 
outcome have differed 
between intervention 
groups? 
PN   
4.3 Were outcome 
assessors aware of the 
intervention received by 
study participants? 
PY 
Although laboratories were 
blinded to the 
randomisation scheme 





4.4 If Y/PY/NI to 4.3: 
Could assessment of the 
outcome have been 
influenced by knowledge 
of intervention received? 
PY 
  
4.5 If Y/PY/NI to 4.4: Is it 
likely that assessment of 
the outcome was 
influenced by knowledge 
of intervention received? 
NI 
Risk of bias 
judgement 






5.1 Were the data that 
produced this result 
analysed in accordance 
with a pre-specified 
analysis plan that was 
finalized before unblinded 
outcome data were 
available for analysis? 
NI No protocol available 
5.2 ... multiple eligible 
outcome measurements 
(e.g. scales, definitions, 
time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible 
analyses of the data? 
N   







Risk of bias 
judgement 






Appendix D Risk of bias in ENDS RCTs 












n at 6 
months 
Results   Weight 1 





1.1 Was the allocation sequence 
random? 
Y 
Computerised block randomisation and centrally administered allocation 
via telephone 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N   
Risk of bias judgement Low   
Bias due to 
deviations 
2.1.Were participants aware of their 
assigned intervention during the 
trial? 








2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NI not reported 
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
Y   








3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N Lost to follow was greater than the number of events recorded 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N 
Missing data was handled by assuming that participants with missing 
smoking status were missing. However, as the lost-to follow-up was not 
balanced across groups there is a still a high risk of bias 
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 





3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
Y 
Only protocol violations explained 
 
Lost to follow-up proportion was different in the treatment arms 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
N   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
N 
According to the paper "Research assistants undertaking outcome 
 
assessments used a list generated by the trial database 
 
giving no indication of product allocation."(p1631) 
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NA 




5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 






5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible analyses of 
the data? 
N ITT, PP and CC analyses all reported 
Risk of bias judgement Low   
Overall bias Risk of bias judgement High   
      
      
Unique ID S2 Study ID ECLAT Assessor JQ 
























n at 6 
months 





1.1 Was the allocation sequence 
random? 
Y Computer generated. 
 
No report of how participants found out which treatment group they were 
allocated to 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
NI 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N 
Although the p value for differences in mean age across the groups was 
significant at the 0.05 level and education level was almost statistically 
significant at this level. Smoking characteristics, which are more likely to 
be prognostic were balanced across the treatment arms. 
Risk of bias judgement 
Some 
concerns 
No report of how participants found out which treatment group they were 
allocated to 






2.1.Were participants aware of their 
assigned intervention during the 
trial? 
N 
Trial reported to be double blind and identical packaging 2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
PN 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NA   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 




2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y ITT analysis for smoking cessation (table 2) 
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   
Risk of bias judgement Low   




3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N The lost to follow-up rate was higher than the number of events 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
Y Reasons for lost to follow-up were not given 
 
There was a greater drop-out rate in the ENNDS group 
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
Y 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 




4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
N Double-blind 
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NA 






5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
NI no protocol found 
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N cessation measured in standard way 
5.3 ... multiple eligible analyses of 
the data? 
N Both ITT and PP analyses presented 




Overall bias Risk of bias judgement High   




      
Unique ID S3 Study ID Halpern Assessor JQ 
















  Journal article(s) with results of the trial;  Trial protocol;  Statistical 





n at 6 
months 
Results   Weight 1 





1.1 Was the allocation sequence 
random? 
NI 
Enrolled via web-based system 1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N 
Statistical testing showed that only the education level baseline 
characteristic was different at the 0.05 level. Smoking characteristics 




Risk of bias judgement Low   






2.1.Were participants aware of their 
assigned intervention during the 
trial? 
Y 
Participants were sent brief descriptions of their assigned interventions 2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NI   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   




Bias due to 
missing 
3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N 
This trial does not clearly report lot to follow-up although its clear there 
was a massive drop-out rate. The study authors defined an engaged 
cohort as those who had logged on to the trial website at least once. 






who were not 'engaged' in the e-cg group received no treatment. In the 
usual care group on 15.9% were engaged and 21.1% of the e-cigarette 
group were engaged 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
Y 
  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
Y 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
Y 
The usual care group did not have to log on to the trial website to access 
their treatment material whereas the e-cigarette group did. Surveys 
collecting results were administered through the website. Protocol states 
use of a web---based platform to collect all self---report information 
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
NA   
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 












5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
Y   
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible analyses of 
the data? 
N   
Risk of bias judgement Low   
Overall bias Risk of bias judgement High   
      
      
Unique ID S4 Study ID Lee Assessor JQ 























n at 6 
months 
Results   Weight 1 





1.1 Was the allocation sequence 
random? 
Y 
  1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
PN 
A statistically significant difference in baseline characteristics were 
observed 
 
between the 2 group for age and total smoking amount. It is unclear if 
this difference in a key prognostic factor is big enough to result in bias in 
the intervention effect estimate 
Risk of bias judgement Low   
Bias due to 
deviations 
2.1.Were participants aware of their 
assigned intervention during the 
trial? 








2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
Y 
4 participants originally assigned to the EC versus 14 assigned to the 
NRT group withdrew before treatment. 75 were originally assigned to 
each arm 
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
Y   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
N   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   
Risk of bias judgement High   




3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N 
The number of people who did not received treatment and therefore 
were not assessed in the NRT arm was close to the number of events 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N No information on how missing data was imputed in the ITT analysis 
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 




3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
Y 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
N   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
N   
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NA 






5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
NI no protocol found 
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 




5.3 ... multiple eligible analyses of 
the data? 
PN   




Overall bias Risk of bias judgement High   
      
      
Unique ID S5 Study ID TEC Assessor JQ 




















n at 6 
months 
Results   Weight 1 















Allocation was only revealed once the participant was logged in the 
system by staff 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N   
Risk of bias judgement Low   






2.1.Were participants aware of their 
assigned intervention during the 
trial? 
Y 
Authors state they were unable to blind 2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NI   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
PY 
One participant in each group died during the trial and was not included 




2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   








3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N 
19.8% drop-out rate in e-cig arm and 24.6% in NRT arm at 6 months. 
Event rate in the E-cig arm was 35.4% at 26 weeks post quit date but 
only 25.1% in the NRT arm. Drop-out rate in NRT arm is very close to 
event rate. 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
Y 
To assess the effect of missing data on the primary outcome, authors 
conducted four prespecified sensitivity analyses. The 
 
result did not change substantially in the four 
 
sensitivity analyses (relative risk, 1.75 to 1.85; P≤0.001 for all 
comparisons) 
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
NA 
  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
NA 
Risk of bias judgement Low   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 




4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
Y   
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 
been influenced by knowledge of 
intervention received? 
Y 




However, at 52 weeks when self-reported data was also verified the 
cessation results did not change direction 
4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
PN 









5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
Y Protocol available and amendments listed 
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible analyses of 
the data? 
N   
Risk of bias judgement Low   








      
























n at 6 
months 
Results   Weight 1 





1.1 Was the allocation sequence 
random? 
Y 
A randomization list using a permuted block design (40 blocks of 6 
participants randomly assigned to 1 of the 3 treatment groups) have 
been previously prepared by an independent personnel unit and labelled 
with the progressive number applied to the  packaging containing e-
cigarettes and liquid cartridges with or without nicotine (Group 1 and 
Group 2). 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 




Risk of bias judgement Low   






2.1.Were participants aware of their 
assigned intervention during the 
trial? 
N 
Double-blind 2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
N 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NA   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y intention to treat 
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   
Risk of bias judgement Low   
Bias due to 
missing 
3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N 
The number of dropouts (25.7% in the ENDS group, 27.1% in the NRT 







3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
NI 
Reasons for lost to follow-up not given 
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
NI 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
PN   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
N Double-blind 
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NA 
Risk of bias judgement Low   
Bias in 
selection of 
5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 







finalized before unblinded outcome 
data were available for analysis? 
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible analyses of 
the data? 
N   
Risk of bias judgement Low   
Overall bias Risk of bias judgement High   
      
      

























on at 6 
months 
Results   Weight 1 





1.1 Was the allocation sequence 
random? 
NI 
participants were randomised 
 
to the control or intervention group, in a 1:1 ratio using 
 
random permuted blocks of variable size (2, 4 or 6). The 
 
allocation schedule was generated by a statistician with 
 
no other involvement in the study, and randomisation 
 
was performed using a secure password-protected 
 
web-based system. There were no stratification factors. 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N Some differences in dental health markers 
Risk of bias judgement Low   






2.1.Were participants aware of their 





were asked not to disclose their smoking status or 
 
methods of smoking cessation during the assessment 
 
appointments. 
2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 





2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NI   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   








3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N Number of events was lower than the number of drop-outs 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
PY 
According to study authors those participants lost to follow-up appeared 
to 
 
have higher eCO and FTND readings and more severe 
 
periodontal diseases at baseline. Although drop out was similar in both 
arms 
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 





Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
N   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
PN Participant were asked not to reveal their assignment 
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NA 






5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
Y   
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
N   
5.3 ... multiple eligible analyses of 
the data? 




Risk of bias judgement Low   
Overall bias Risk of bias judgement High   
      
      
Unique ID S8 Study ID 
Hatsuka
mi 2019 
Assessor   



















Results   Weight 1 









1.2 Was the allocation sequence 





enrolled and assigned to 
interventions? 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N   










2.1.Were participants aware of their 
assigned intervention during the 
trial? 
Y 
  2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 
NI   
2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 












3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N 
There was 23.7% dropout rate in the ENDS arm and 30.3% in the NRT 
arm 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
NI 
  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
NI 
Risk of bias judgement High   
Bias in 
measureme
nt of the 
outcome 
4.1 Was the method of measuring 
the outcome inappropriate? 
N   
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
N   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
Y   
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 












5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
NI protocol not available 
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
PN   
5.3 ... multiple eligible analyses of 
the data? 
PN   




Overall bias Risk of bias judgement High   
      
      
Unique ID S9 Study ID Lee 2018 Assessor JQ 






















Results   Weight 1 










was concealed by consecutively numbered, sealed, opaque envelopes. 
1.2 Was the allocation sequence 
concealed until participants were 
enrolled and assigned to 
interventions? 
Y 
1.3 Did baseline differences 
between intervention groups suggest 
a problem with the randomization 
process? 
N   
Risk of bias judgement Low   






2.1.Were participants aware of their 
assigned intervention during the 
trial? 
Y 
  2.2.Were carers and people 
delivering the interventions aware of 
participants' assigned intervention 
during the trial? 
Y 
2.3. If Y/PY/NI to 2.1 or 2.2: Were 
there deviations from the intended 
intervention that arose because of 
the experimental context? 




2.4 If Y/PY to 2.3: Were these 
deviations likely to have affected the 
outcome? 
NA   
2.5. If Y/PY/NI to 2.4: Were these 
deviations from intended intervention 
balanced between groups? 
NA   
2.6 Was an appropriate analysis 
used to estimate the effect of 
assignment to intervention? 
Y   
2.7 If N/PN/NI to 2.6: Was there 
potential for a substantial impact (on 
the result) of the failure to analyse 
participants in the group to which 
they were randomized? 
NA   








3.1 Were data for this outcome 
available for all, or nearly all, 
participants randomized? 
N Very small study total N=30, 20% at 8 weeks in NRT and 10% for ENDS 
3.2 If N/PN/NI to 3.1: Is there 
evidence that result was not biased 
by missing outcome data? 
N   
3.3 If N/PN to 3.2: Could 
missingness in the outcome depend 
on its true value? 
PN 
3/5 lost to follow-up were lost because surgery did not go ahead.  
3.4 If Y/PY/NI to 3.3: Is it likely that 
missingness in the outcome 
depended on its true value? 
NA 
Risk of bias judgement Low   
Bias in 
measureme
4.1 Was the method of measuring 
the outcome inappropriate? 




nt of the 
outcome 
4.2 Could measurement or 
ascertainment of the outcome have 
differed between intervention 
groups? 
N   
4.3 Were outcome assessors aware 
of the intervention received by study 
participants? 
Y 
Outcome adjudicators were blinded 
 
wherever possible, but some participants unintentionally unblinded the 
investigators while 
 
reporting side-effects (e.g., reporting a bad taste with inhalation). 
4.4 If Y/PY/NI to 4.3: Could 
assessment of the outcome have 




4.5 If Y/PY/NI to 4.4: Is it likely that 
assessment of the outcome was 
influenced by knowledge of 
intervention received? 
NI 






5.1 Were the data that produced this 
result analysed in accordance with a 
pre-specified analysis plan that was 
finalized before unblinded outcome 
data were available for analysis? 
Y   
5.2 ... multiple eligible outcome 
measurements (e.g. scales, 
definitions, time points) within the 
outcome domain? 
PN   
5.3 ... multiple eligible analyses of 
the data? 
N   










Appendix E Bayesian random effects model results of 
NMA 
 
Results for main anlaysis 
Results on the Log Risk Ratio scale 
 
Iterations = 250010:750000 
Thinning interval = 10  
Number of chains = 3  
Sample size per chain = 50000  
 
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
 
         Mean     SD  Naive SE Time-series SE 
d.B.A -0.1349 0.2938 0.0007585      0.0008638 
d.B.C -0.5932 0.3663 0.0009459      0.0012108 
d.B.D -1.2246 0.4500 0.0011619      0.0017412 
sd.d   0.3666 0.2707 0.0006990      0.0013598 
 
2. Quantiles for each variable: 
 
          2.5%     25%     50%       75%    97.5% 
d.B.A -0.68751 -0.2941 -0.1580  0.009609  0.50283 
d.B.C -1.36123 -0.8081 -0.5796 -0.363856  0.09019 
d.B.D -2.18394 -1.4958 -1.2006 -0.926185 -0.41082 
sd.d   0.02053  0.1733  0.3090  0.493135  1.07303 
 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
14.87739 12.38581 27.26320  
 





Results for inconsistency model with unrelated mean relative 
effects 
 
Results on the Log Risk Ratio scale 
 
Iterations = 250010:750000 
Thinning interval = 10  
Number of chains = 3  
Sample size per chain = 50000  
 
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
 
         Mean     SD  Naive SE Time-series SE 
d.A.B  0.1268 0.3362 0.0008681       0.000944 
d.A.C -0.5779 0.8030 0.0020732       0.002983 
d.B.C -0.6044 0.4654 0.0012017       0.001405 
d.B.D -1.2438 0.4806 0.0012409       0.001695 
sd.d   0.4271 0.3147 0.0008125       0.001569 
 
2. Quantiles for each variable: 
 
          2.5%      25%     50%      75%   97.5% 
d.A.B -0.61129 -0.03266  0.1510  0.30196  0.7788 
d.A.C -2.29487 -1.05575 -0.5307 -0.05407  0.8800 
d.B.C -1.58905 -0.86256 -0.5860 -0.32519  0.2746 
d.B.D -2.28499 -1.52530 -1.2173 -0.93310 -0.3768 
sd.d   0.02523  0.19943  0.3566  0.57642  1.2638 
 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
15.51717 13.35178 28.86895  
 






Results for sensitivity analysis 1: excluding lighter smokers 
Results on the Log Risk Ratio scale 
 
Iterations = 250010:750000 
Thinning interval = 10  
Number of chains = 3  
Sample size per chain = 50000  
 
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
 
         Mean     SD  Naive SE Time-series SE 
d.B.A -0.1360 0.2565 0.0006622       0.000754 
d.B.C -0.5500 0.3412 0.0008810       0.001200 
d.B.D -0.9670 0.4657 0.0012024       0.001770 
sd.d   0.3208 0.2104 0.0005431       0.001018 
 
2. Quantiles for each variable: 
 
          2.5%     25%     50%      75%    97.5% 
d.B.A -0.61840 -0.2867 -0.1573 -0.00109  0.43424 
d.B.C -1.25402 -0.7626 -0.5401 -0.32707  0.09641 
d.B.D -1.93747 -1.2599 -0.9514 -0.65800 -0.09014 
sd.d   0.01913  0.1600  0.2841  0.44462  0.82416 
 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
12.57966 11.05911 23.63876  
 
14 data points, ratio 0.8985, I^2 = 0% 
Results for sensitivity analysis 2: excluding unvierifed data 
Results on the Log Risk Ratio scale 
 
Iterations = 250010:750000 
Thinning interval = 10  




Sample size per chain = 50000  
 
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
 
          Mean     SD Naive SE Time-series SE 
d.B.A  0.06673 0.4075 0.001052       0.001205 
d.B.C -0.57420 0.3926 0.001014       0.001327 
d.B.D -1.22670 0.4711 0.001216       0.001807 
sd.d   0.40030 0.3245 0.000838       0.001735 
 
2. Quantiles for each variable: 
 
          2.5%     25%      50%     75%   97.5% 
d.B.A -0.78166 -0.1454  0.07095  0.2844  0.8869 
d.B.C -1.41014 -0.7936 -0.55734 -0.3346  0.1596 
d.B.D -2.23874 -1.5006 -1.20207 -0.9226 -0.3754 
sd.d   0.01612  0.1573  0.32067  0.5550  1.2662 
 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
12.80995 10.61698 23.42693  
14 data points, ratio 0.915, I^2 = 0% 
Results for sensitivity analysis 3: excluding low dose nicotine 
Results on the Log Risk Ratio scale 
 
Iterations = 250010:750000 
Thinning interval = 10  
Number of chains = 3  
Sample size per chain = 50000  
 
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
 
         Mean     SD  Naive SE Time-series SE 
d.B.A -0.2865 0.3318 0.0008566      0.0009122 




d.B.D -1.2198 0.4435 0.0011452      0.0019979 
sd.d   0.3272 0.2974 0.0007679      0.0017127 
 
2. Quantiles for each variable: 
 
           2.5%     25%     50%     75%    97.5% 
d.B.A -0.954077 -0.4342 -0.2978 -0.1504  0.43686 
d.B.C -1.368933 -0.8056 -0.5844 -0.3770  0.05521 
d.B.D -2.170003 -1.4815 -1.1939 -0.9272 -0.42462 
sd.d   0.009674  0.1098  0.2430  0.4522  1.14731 
 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
12.34386 10.28253 22.62639  
 
14 data points, ratio 0.8817, I^2 = 0% 
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